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Major Field: ORGANIC CHEMISTRY 
Abstract: The first part of this work involved the synthesis of chemical probes to the inhibiton of 
the BfrB/Bfd protein interaction limiting the bioavalibility of Fe3+ in Pseudomonas aeruginosa as 
potential antibiotic candidates  Previously, our group synthesized substituted 4-aminoisoindoline-
1,3-diones which exhibited promising enzymatic inhibition of the BfrB/Bfd protein interaction in 
the micromolar range. One of the primary goals of this project was to synthesize analogs in the 
nanomolar range. To achieve this, we synthesized 1- and 3-carbon linked analogs of substituted 4-
aminoisoindoline-1,3-diones. 
• Incorporation of new substituted benzaldehydes: This can be achieved by starting with
relatively inexpensive materials. Based on molecular modeling, we previously predicted
that the incorporation of these functionalities in analogs of 4-aminoisoindoline-1,3-dione
would increase the protein inhibitory effect. We subsequently designed and synthesized a
new series of 10 compounds incorporating various substituents on the benzaldehyde
component. For the purpose of this study, the 1° and 3-carbon linkers were not altered in
the synthesis.
• Altering the carbon linker BfrB/Bfd chemical probes: Other modifications to 4-
aminoisoindoline-1,3-dione were also made by decreasing the 3-atom carbon linker to a 1-
atom linker and incorporating a phenoxyethoxy linker. We were interested in comparing
the activity data of the 1-carbon, with 3-carbon and phenoxyethoxy linked 4-
aminoisoindoline-1,3-diones using similar substitution patterns in substituted
benzaldehydes.
This work also involved the synthesis of  anti-cancer agents. Flexible Heteroarotinoids (Flex-Hets) 
are a class of substituted di-aryl compounds that exhibit potent anti-cancer activity without toxicity. 
Previously, our group developed a sulfur containing heteroarotinoid SHetA2 (NSC 721689), which 
exhibited promising activity against 62 different cancer cell lines at micromolar concentration with 
excellent differentiation between normal and cancer cells. This work focused on modifiying the 
linker unit of the SHetA2 compound.  
• This study also focused on the synthesis of various analogs of SHetA2 and their evaluation
against ovarian cancer cell line A2780. Structural modifcations were made to the linker
unit and Ring B of SHetA2 in order to improve aqueous solubility, potency and efficacy.
The second part of this work involved devising new methods for preparing bioactive heterocylic 
scaffolds.  These methods are summarized below.  
• Synthesis of naphthoates, dihydroquinolines, and naphthyridine carboxylates was
accomplished via the Morita-Bayliss-Hillman reaction.
• A four-step synthesis to 2-fluoro-5-nitronicontinaldehyde was facilitated by reduction of
an ester by DIBAL-H.
• An efficient tandem reaction was designed to synthesize 4-chromanone using 20 mol% of
bismuth(III) triflate.
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SYNTHESIS OF SMALL MOLECULES AS POTENTIAL ANTIBIOTIC AND 
ANTICANCER CANDIDATES 
1.1 Introduction 
The development of new antibiotics has always been at the forefront of medicine. As the 
population of the world continues to increase, scientists must formulate and improve 
methodologies for antibiotic development. Antibiotic-resistant bacteria have evolved into a 
major concern to health professionals worldwide.1 The strict regulations set by the Food and 
Drug Administration (FDA) put a strain on the approval of antibiotics, causing reduced 
progress in pharmaceutical research.1 During the last 21 years, only two new classes of 
antibiotics (Figure 1.1) have been approved by the FDA and other international drug 
agencies.1 The efforts of pharmacuetical companies in antibiotic research is challenged by 
economical, regulatory and scientific issues.1 It is critical to develop new classes of antibiotic 
candidates in an efficient manner, in order to mitigate their strict approval process. 
























A recent focus in our group has been dedicated to the synthesis of a series of potential antibiotic 
candidates which disrupt iron homeostasis in Pseudomonas aerugionosa cells.3-5 Bacteria
rely heavily on iron from a nutritional and chemical standpoint.3-5 Iron typically exists in two 
oxidation states: Fe3+ greatly reduced the bioavailability due to its insolubility4  and, Fe2+, which 
is more soluble in an aqueous solution but can often be readily converted to Fe3+ via an O2 
oxidization mechanism.4 In response to insufficient iron availability, bacteria have evolved a 
number of mechanisms to counter the effects of their iron-dependence.6 An example of these 
mechanisms is the utilization of Fe2+ importers, “siderophores” which are responsible for chelating 
ferric ions in order to produce a ferric-siderophore complex that is utilized in the transportation of 
iron to the bacterial cytoplasm.7-8 Ferric-siderophore complexes are generally produced at a higher 
pH, where normally, iron is present as insoluble compounds (Figure 1.2).8 These chelating ligands 
have low-molecular weight, and are known to have a high affinity for Fe3+.8 Various studies have 
confirmed that iron levels in bacterial pathogens are crucial to their pathological activity.8  
Figure 1.2 Maintenance of cellular iron homeostasis under deficient and replete conditions9 
Several defense mechanisms of bacteria are crucial to their ability to maintain iron homeostasis. 
To maintain iron homeostasis, bacteria must employ various strategies surrounding the synthesis 
and production of iron scavenging systems.4 Bacteria accomplish this by capturing and importing 
iron-scavenger complexes and maintaining proper iron storage in several iron-storage proteins.4  
3 
Two of the most studied iron storage proteins in P. aeruginosa  cells are ferritins (FtnA) and heme-
containing bacterioferritins (BfrB). Recently, the relationship between the iron mobilization from 
BfrB into ferredoxin Bfd was unclear to the scientific community.4-6 However, recent studies 
suggest that the iron storage protein (BfrB) plays a key role in bacterial iron homeostasis.5 The 
focus of this work is to synthesize and optimize small molecules that inhibit the BfrB:Bfd protein 
interaction resulting in deregulation of cytosolic iron levels in P. aeruginosa  cells. Iron in the form 
of Fe2+ is necessary for normal growth and function of the Gram negative bacteria P. 
aeruginosa.  Bacterioferritin (BfrB) is an iron storage protein that stores iron in the form of an Fe3+ 
mineral.  When iron is needed by P. aeruginosa, bacterioferritin-associated ferredoxin (Bfd) binds 
to the outer shell of BfrB and facilitates the transfer of an electron from ferredoxin reductase (FPR) 
into BfrB to reduce the Fe3+ to Fe2+.  Interruption of this interaction deprives P. aeroginosa of the 
Fe2+ it needs and the bacteria die.  The focus of this work is to synthesize and optimize small 
molecules that inhibit the BfrB:Bfd protein interaction resulting in decreased cytosolic iron levels 
in P. aeruginosa cells.  This strategy exploits a new strategy for treating afflictions deriving from 
P. aeruginosa.4-9 We are interested in improving the activity of BfrB:Bfd protein inhibitors by
incorporating the following changes: 
1) incorporating new substituted benzaldehydes and
2) altering the 3–carbon linker unit
Retrosynthetic analysis of potential targets 4 from 5 and 6 involving a single-and multistep 












Figure 1.3 Rationale for designing substituted 4-aminoisoindoline-1,3-diones 
1.2. Modification of Analogs 
1.2.1 Incorporation of new substituted benzaldehydes 
Modifications to the substituents on the benzaldehyde component have been envisioned to enhance 
the BfrB:Bfd protein inhibition.4-6 Careful consideration and analysis led to utilization of chlorine 
and bromine substituted salicylaldehydes. Incorporation of these halogens would increase the 
molecular weight of our targeted molecule, and more importantly, it would allow for a “tighter” fit 
in the BfrB:Bfd active site, due to the presence of the larger halogen atoms. In addition, the effects 
of varying the position of the halogen substituents of 5 are critical to our investigation. Alternating 
between chlorine and hydroxyl functionalities at R2 and R3 may shed light on the potential 
inhibition effects of hydrogen bonding versus electron withdraw groups. 
One of our most active compounds bears a hydroxy moiety at the R2 position of 4. Additional; 
flexibility can be added to the molecule by incorporating a CH2OH or a O(CH2)2OH at this position. 
This can be achieved by starting with relatively inexpensive materials. Based on molecular 

































would increase the protein inhibitory effect. We subsequently designed and synthesized a new 
series of 10 compounds incorporating various substituents on the benzaldehyde component. For 
the purpose of this study, the 1- and 3-carbon linkers were not altered in the synthesis. We are 
currently waiting on the activity assessment of these compounds, for comparison to previously 
synthesized analogs.  
1.2.2. Results and discussion for the incorporation of new substituted benzaldehydes for 
BfrB/Bfd chemical probes.  
The syntheses of substituted 4-aminoisoindoline-1,3-dione analogs incorporating a 1-atom linker 










Scheme 1.1. Synthesis of analog 12 
tert-Butyldimethylsilyl (TBS) protection of 7 with imidazole in DMF afforded 8 in 92% after 
purification by silica gel chromatography.10-15 The acrylate intermediate 8 was obtained under 
Horner-Wadsworth-Emmons conditions using a slight excess of triethyl phosphonoacetate (TEPA) 
and 60% NaH dispersed in mineral oil.16 The addition sequence for this reaction proved to be 
important as an increase in yield was observed when NaH was added to a solution of TEPA in THF. 








































chromatography to generate 9 in 97%. Reduction of the ester moiety using DIBAL-H can be 
troublesome if the temperature and mode of addition are not carefully monitored.17 Therefore, it is 
imperative that the temperature does not exceed -65 oC during the addition. Additional dry ice may 
be added to maintain the temperature at or below -65 oC throughout the course of the reaction. The 
intermediate 10 can be isolated and characterized by 1H and 13C NMR. The success of the reductive 
amination step, between 6 and 1catalyzed by AcOH relies heavily on the purity of the aldehyde 
component and the volume of DMF.19-22 The use of excess solvent impedes formation of the imine 
intermediate which can further decompose upon addition of the reducing agent. Morever, it is 
imperative that 1.2-1.5 mL of anhydrous DMF be used for reactions of 2-3 mmol of the aldehyde 
component. In addition, the reactions must be strirred at 23 oC for 1 h prior to the addition of the 
reducing agent.19  The coupled product, 11 can be obtained in 12% yield after purification by 
column chromatogrpahy on silica gel pre-treated with 3-hydroxy-2-methyl-4-pyrone. The silyl 
deprotection of 11 is achieved by the addition of 2 equivalents of 1 M tetrabutylammonium fluoride 
(TBAF) in THF at 23 oC. The desired analog 12 is obtained by purification using pyrone-treated 
silica in 78%. A similar set of reaction conditions can be used to synthesize analogs 13, 14, 15, 16 










Figure 1.4 Analogs of 4-amino-isoindoline-1,3-diones with a 3 carbon linker 
The incorporation of a hydroxymethyl substituent on the aldehyde component can achieved 
according to the route outlined in (Scheme 1.2).  
 
Scheme 1.2 Synthesis of analog 24 
Reduction of 18  to 19 was achived using 0.25 equiv. of NaBH4.18 The reducing agent was added 
portion-wise, while simultaneously monitoring the reaction via TLC to minimize over reduction to 
the diol. Because the reaction only proceeds in 70-75%, the starting material was recycled to 
maximize the output of 19. Intermediate 20 was produced via reaction with tert-butyldimethylsilyl 
chloride in the presence of imidazole in DMF. The corresponding acrylate 21 was synthezied using 
60% NaH and TEPA in THF, and was subsequently hydrogenated and reduced with DIBAL to 













































































and 22 to obtain 23. Removal of the TBS group with 1 M TBAF in THF and purification with 
pyrone-treated silica gel afforded 24 in 18%.  A similar route to analog 31 from 25 is illustrated in 
(Scheme 1.3). 
 
Scheme 1.3 Synthesis of analog 31 
1.3. Altering the carbon linker of BfrB/Bfd chemical probes 
Other modifications to 4 were also made by decreasing the 3-atom carbon linker to a 1-atom 







Figure 1.5 Rationale for altering carbon linker in 4-amino-isoindoline-1,3-diones 











































































We were interested in comparing the activity data of the 1-carbon and phenoxyethoxy-linked 4-
aminoisoindoline-1,3-diones using similar substitution patterns in 5. A probable route to a  
1-carbon linker analog is shown in (Scheme 1.4).
Scheme 1.4 Synthesis of analog 34 
1.3.1. 1 Results and Discussion for the 1-carbon linker BfrB/Bfd chemical probes 
Reaction between 33 and 6 did not proceed at room temperature.19 Initial trial runs using our 
previously mentioned conditions failed to afford 34 in good yield. Therefore, in order to maximize 
the converstion to 34, the reaction between of 6 and 33 in DMF and AcOH required heating at 90 
oC for no more than 2 h. This can be attributed to the decrease in reactivity of 33 toward the 
nucleophilic attack of 6.19,23 Addition of 6 to 33 formed a thick slurry, which then turned clear once 
the reaction reached 90 oC. Allowing the reaction to proceed at 90oC for longer than 2 h did not 
improve the outcome. After allowing the reaction to proceed for 2 h at 90 oC, it was then cooled to 
0 oC prior to the portion-wise addition of the reducing agent.19 The expected product 35 was 
obtained after purification by column chromatography. A similar set of reaction conditions was 




















Figure 1.6 Analogs of 4-aminoisoindoline-1,3-diones with a 1 carbon linker 
1.3.2. Results and discussion for the phenoxyethoxy linker analogs. 
The synthesis of 43  began with O-alkylation of 38 with ethyl bromoacetate in CH3CN with K2CO3 
(Scheme 1.5). This proceeeded in 95% yield following purification by silica gel chromatography.25-
28 Treatment of 39 with NaBH4 afforded 41 without further purification in 63%. Protection of 40 
with tert-butyldimethylsilyl chloride in the presence of imidazole led to the TBS-protected 
intermediate, which was subsquently reduced to 41 with DIBAL in CH2Cl2 at -78 oC in 83% yield. 
The reductive amination sequence between 41 and 6 proceeded after chromatographic purification 
on pre-treated silica to gel provide 42 in 15% yield. Removal of the TBS protecting groups with 1 




















Scheme 1.5 Synthesis of analog 43 
A similar set of reaction conditions was used to synthesize analogs 44 and 45. 





























































1.4 Anticancer agents 
In addition to the synthesis of  BrfB/Bfd chemical probes, this study also focused on the synthesis 
of various analogs of SHetA2 and their evaluation against the A2780 ovarian cancer cell line.31-33 
Structural modifcations were made to the linker unit and Ring B of SHetA2 (Figure 1.8) in order 
to improve aqueous solubility, potency and efficacy.  
Figure 1.8 Anticancer agent SHetA2 
Previously, our group synthesized a handful of second-generation flexible heteroarotinoids 
differentiating the linker unit by incorporating cinnamamide linked to the sulfur-containing 
heterocycle found in SHet-A2.30 (Figure 1.9)  
Figure 1.9 Acrylamide modification in SHetA2 
While several structural modifications were made to the linker unit, the biological activity data of 
the synthesized compounds failed to compare to that of SHetA2.30 In addition, last year our group 
finalized the synthesis of oxygen containing analogs, which proved to be more potent against 
ovarian cancer than SHetA2.34 
1.4.1 Altering the linker unit of SHetA2 
Increasing the 3-atom linker unit in SHetA2 was envisioned to enhance potency and hydrogen 



















mortalin (HSPA9).33 This interaction prohibits the binding of mortalin to p53 and bcl-2, two 
proteins that regulate apoptosis of cells.33 Our lead compound SHetA2 displaces the protein p53 
and bcl-2 from mortalin causing programmed apoptosis.32,33 Based on these observations, the focus 
of this work was to increase hydrogen bonding capabilities to potentiate this interaction further. 
1.4.2. Results and discussion for altering the linker unit of SHet-A2 
The synthesis of the SHetA2 analogs was performed in 5-8 steps according to the following 
procedures30,34 outlined in (Scheme 1.6)  
Scheme 1.6 Synthesis of thiochroman heterocycle 51 
Initially, 4-acetamidothiophenol 46 underwent a Michael addition with mesityl oxide 47 in the 
presence of triethylamine. The reaction was optimized by using a two-fold excess of 47 and 
triethylamine and adding the reagents in a dropwise fashion.30 Intermediate 48 was treated with 3 
equivalents of MeLi at -45 oC to afford the tertiary alcohol 49. A Friedel-Craftscyclization of 49  
with AlCl3 in chlorobenzene produced the desired thiochroman derivative 50 in 89% yield. The 
acetyl group was then removed by action of 6 M HCl in MeOH to produce the hydrochloride amine 
salt, which was neutralized by the addition of NaHCO3 in water to afford (51) as a brown oil in 
91% yield.  
The synthesis of the oxygen chroman heterocycle was performed in a 6-step reaction sequence as 






































Scheme 1.7 Synthesis of chroman heterocycle 58 
 
 The synthesis of 54 was achieved by following a procedure similar to that described by Dawson 
and coworkers.35 Phenol 52 was added dropwise to an oil-free suspesion of NaH in THF at 0 oC. 
After stirring the reaction mixture for 15 minutes, 3-methylbut-2-enoyl chloride (5) was added 
dropwise, and the reaction mixture was allowed to gradually warm to room temperature. Work-up 
and purification by silica gel chromatography generated 54 as a colorless oil in 95% yield. The aryl 
ester 54 was treated with AlCl3 in DCM to afford the desired chromanone 55. Subsequent treatment 
with MeLi at 0 oC afforded the diol 56 as a white solid in 90% yield. The chroman derivative 57 
was obtained by a cyclodehydration sequence using concentrated phosphoric acid at 100 oC. The 
chroman derivative 57 was nitrated using nitric acid in acetic anhydride at -15 oC (ice/methanol 
bath) to produce the 6-and 8-nitro isomers which were carried on to a reduction promoted by iron 
powder and ammonium chloride in aqueous ethanol.36 The target 58 was obtained after purification 
by silica gel chromatography.33Compounds 51 and 58 were converted to their respective 
isothiocyanates according to the known procedure37 (Scheme 1.8)  and were combined with 













































Scheme 1.9 Synthesis of 3- and 4-atom linker targets 
 
These synthesized analogs were screened to identify structural features important for cancer cell 
inhibition activity.  SHetA2 was used as a standard for comparison.  The biological effects of the 
compounds were assessed using a cytotoxicity assay on the human A2780 ovarian cancer cell line 
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3.17 100 93.17 ± 2.37 
   63a 
7.63 94.68 76.61 ± 4.99 
63b 
8.12 14.45 11.67± 2.24 
    64a 
6.38 22.31 18.02 ± 1.81 
64b 
6.04 19.29 15.58 ± 1.55 
64c 
5.33 8.39 6.78 ± 1.69 
  65 
7.24 6.40 5.17 ± 3.49 
Table 1.1. Activity data for analogs 64a-b, 65a-c and 66 
Of the synthesized analogues, compound 63a proved most active demonstrating 77% cancer cell 
growth inhibition compared to that of SHetA2 (93%). However, the addition of the hydrazine group 
in the linker unit seemed to reduce the overall potency. All of the other derivatives were found to 







































































In summary, we have synthesized various compounds as potential antibiotic and anti-cancer 
candidates.  
1.5.1 Incorporation of new substituted benzaldehydes  
In this study, we have successfully prepared new analogs of 4 from substituted benzaldehydes. The 
syntheses of these analogs were performed in a 5-8 steps. Our interests lie in the results of the 
incorporation of various substituents on the benzaldehyde component and their inhibition of the 
BfrB/Bfd protein interaction.  
1.5.2 Altering the carbon linker in BfrB/Bfd chemical probes 
In an effort to further block the BfrB/Bfd protein interaction, the synthesis of a single carbon linker 
analogs was achieved with improved yields. Our interests lie in comparing the activity between our 
3-carbon linker and 1-carbon linker chemical probes. Moreover, the addition of polar groups to the 
linker unit could increase the solubility and hydrogen bonding potential of our analogs to 
surrounding amino acid residues.4-9 We are anxiously waiting the activity data pertaining to 
substitution effects on the pertubation of the BfrB/Bfd protein interaction.  
1.5.3 Synthesis of Anticancer agents 
In this study, we attempted to synthesis analogs of SHetA2 with extended linker units. 
Unfortunately, only one analog 63a demonstrated comparable cancer cell inhibition to that of 
SHetA2. It would be a worthy endevaour to alter the thiourea component of 63a to a urea, as well 
as synthesizing a similar compound incorporating the oxygen heterocyclic system. Further 








1.6.1  Incorporation of substituted benzaldehydes in BfrB/Bfd chemical  probes 
General procedure for pyrone treated silica gel: A 3-L sintered-glass funnel suspended on an 
O-ring was charged with one-kilogram of silica gel (Sorbent Technologies CA# 40940-25).  The
silica gel was treated with a solution of  3-hydroxy-2-methyl-4-pyrone (20 mg) in 1 L of MeOH. 
The initial wash (yellow-orange coloring) was discarded. Additionally, the silica gel was washed 
with 500 mL of recycled MeOH (old washings). An additional 1.5 L of fresh MeOH was used to 
rinse the silica gel. The silica gel was transferred to a tray, covered with aluminum foil (poked holes 
to let silica breathe) and was set to air dry at room temperature overnight. Subsequently, the silica 
gel was dried in the oven at 90 °C in 3 h increments. 
General methods: Commercial anhydrous N,N-dimethylformamide was stored under dry N2 and 
transferred by syringe into reactions when needed. Tetrahydrofuran was dried over potassium 
hydroxide pellets and then distilled from lithium aluminum hydride prior to use. All other 
commercial reagents and solvents were used as received. Unless otherwise indicated, all reactions 
were carried out under dry N2 in oven-dried glassware. Reactions were monitored by thin layer 
chromatography (TLC, Analtech No 21521) using silica gel GF plates. Preparative separations for 
final compounds were performed by column chromatography on silica gel (Davisil®, grade 62, 60 
- 200 mesh) pre-treated with 3-hydroxy-2-methyl-4-pyrone mixed with UV-active phosphor
(Sorbent Technologies No UV-05) slurry packed into quartz columns. Band elution for all 
chromatographic separations was monitored using a hand-held UV lamp. Melting points were 
uncorrected. IR spectra were run as thin films on NaCl disks. The 1H- and 13C-NMR spectra were 
measured in the indicated solvent at 400 MHz and 100 MHz, respectively, using tetramethylsilane 
as the internal standard with coupling constants (J) given in Hz. 
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Synthesis of (12) 
4-(2-((tert-Butyldimethylsilyl)oxy)ethoxy)benzaldehyde 8.  A stirred solution of 4-(2-
hydroxyethoxy)benzaldehyde 7 (1.44 g, 8.65 mmol) in DMF (10 mL) was cooled to 0 oC under 
nitrogen atmosphere and imidazole (1.18 g, 17.3 mmol) was added.  The resulting solution was 
stirred for 20 min and tert-butyldimethylsilyl chloride (1.64 g, 10.4 mmol) was added dropwise as 
a solution in DMF (10 mL) was added dropwise over a period of 15 min.  The reaction mixture was 
warmed to room temperature (23 oC) and stirred until TLC analysis indicated the complete 
conversion of the phenolic compound. The crude reaction was poured into water (50 mL), extracted 
with ether (3 × 40 mL), and the combined organic layers were washed with saturated NaCl (50 
mL). The combined organic layers were dried (Na2SO4) and concentrated under vacuum.  The 
crude product was purified by column chromatography to afford (2.42 g, 92%) of 4-(2-((tert-
butyldimethylsilyl)oxy)ethoxy)benzaldehyde 8 as a colorless oil. IR: 2951, 2931, 2857, 1692, 
1600, 1507, 1258, 908.61 cm-1; 1H NMR (CDCl3): δ; 9.88 (s, 1H), 7.83 (dd, J = 6.9 Hz, 1.9 Hz, 
2H), 7.02 (d, J = 8.7 Hz, 2H), 4.14 (t, J = 4.9, 2H), 4.00 (t, J = 5.2 Hz, 2H), 0.90 (s, 9H),  0.10 (s, 
6H); 13C NMR (CDCl3): δ 190.8, 164.1, 131.9, 129.9, 114.87, 69.6, 61.8, 25.9, -5.2. 
Ethyl (E)-3-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)acrylate (9).  To a stirred, ice-
cold solution of triethylphosphonoacetate (1.92 g, 1.70 mL, 8.5 mmol) in THF (5.0 mL) was added 
a 60% NaH dispersed in mineral oil (340 mg, 8.5 mmol) and the mixture was stirred for 15 min. 
To the resulting reaction mixture was added dropwise TBS protected 4-(2-
hydroxyethoxybenzaldehyde (8, 2.00 g, 7.14 mmol) in THF (15 mL) and the stirred reaction was 
allowed warmed to 23 oC.  After the TLC analysis indicated the complete consumption of starting 











product was extracted into ether (2 × 25 mL), and the organic layer was washed with saturated 
NaCl (15 mL), dried (Na2SO4) and evaporated to afford acrylate 9 (2.11 g, 82%) as a colorless oil.  
This compound was carried forward without further purification. 
Ethyl 3-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)propanoate. (9a) A solution of ethyl 
(E)-3-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)acrylate 9 (2.01 g, 5.74 mmol) in ethanol 
(15 mL) was flushed twice with nitrogen and 10% Pd/C (211 mg, 50% wet) was added.  The 
reaction was stirred at room temperature under H2 (1 atm) for 18 h.  The reaction mass was filtered 
through a Celite® bed and washed with ethanol (2 × 40 mL). The filtrate was concentrated under 
vacuum and purified by silica gel column chromatography to afford ethyl 3-(4-(2-((tert-
butyldimethylsilyl)oxy)ethoxy)phenyl)propanoate (1.97 g, 97%) as a colorless oil. IR: 2957, 2931, 
2859, 1734, 1310 , 1248, 915 cm-1; 1H NMR (CDCl3): δ 7.09 (d, J = 8.6 Hz, 2H),  
6.84 (d, J = 8.7 Hz, 2H), 4.11 (q, J = 7.2 Hz, 2H), 4.02 (t, J = 4.7 Hz, 2H), 3.96 (t, J = 4.9 Hz, 2H), 
2.87 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 7.5 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H), 0.91 (s, 9H), 0.09 (s, 6H); 
13C NMR (CDCl3): δ 173.0, 157.4, 137.7, 129.9, 129.2, 114.6, 69.3, 62.1, 60.4, 36.3, 30.2, 25.9, 
14.2, -5.2. 
3-(4-(2-hydroxyethoxy)phenyl)propanal (10). The ester 9a (1.40 g, 4.0 mmol) prepared above 
was dissolved in dicholoromethane (DCM, 10 mL) and cooled to –78 oC. The solution was treated 
by dropwise addition of 1.5 M DIBAL-H in toluene (2.63 mL, 4.0 mmol) over a period of 30 min. 
Stirring was continued for 2 h at –78 oC until TLC analysis indicated the complete absence of 
starting material. The reaction was quenched at –70 oC by dropwise addition of methanol (10 mL), 
followed by the dropwise addition of 1 M HCl (15 mL). The aqueous layer was separated and 
extracted with DCM (2 × 50 mL).  The combined organic layers were washed with saturated NaCl 
and dried (Na2SO4).  Removal of the solvent under reduced pressure afforded 3-(4-(2-
hydroxyethoxy)phenyl)propanal (1.15 g, 95%) as a colorless oil. IR: 1723, 1508, 1244, 914 cm-1; 
1H NMR (CDCl3): δ 9.81 (t, J = 1.5 Hz, 1H), 7.10 (dd, J = 6.6 Hz, 2.2 Hz, 2H), 6.83 (dd, J = 6.6, 
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2.1 Hz, 2H), 3.99 (d, J = 5.1 Hz, 2H), 3.97 (dd, J = 5.1, 1.7 Hz, 2H), 2.91 (t, J = 7.4 Hz, 2H), 2.75 
(td, J = 8.5, 7.8, 2H), 0.91 (s, 9H), 0.09 (s, 6H); 13C NMR: δ 201.8, 157.5, 132.4, 129.9, 129.8, 
129.3, 129.2, 114.7, 114.4, 69.3, 62.81, 45.6, 27.3, 25.9, 20.5,  
-5.2.
4-((3-(4-(2-((tert-Butyldimethylsilyl)oxy)ethoxy)phenyl)propyl)amino)isoindoline-1,3-dione 
(11) To a solution of  3-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanal (0.96 g, 3.44
mmol) in DMF (1.5 mL) was added AcOH (0.8 mL) and the solution was stirred for 10 min. To 
this reaction mixture, 4-aminophthalimide 6 (0.28 g, 1.72 mmol) was added and stirring was 
continued at 23 oC for 1 h.  An additional 1 mL of DMF was added bringing the volume to 2.5 mL. 
The reaction was cooled to 0 oC and NaBH(OAc)3 (1.13 g, 5.16 mmol) was added subsequently 
portion-wise to the reaction. Stirring was continued at this temperature for 30 min, and then the 
reaction was gradually warmed to 23 oC and stirred for 18 h.  The crude reaction mixture was 
poured into de-ionized water, extracted with EtOAc (3 × 75 mL) and the combined organic layers 
were washed with saturated NaHCO3 (2 × 50 mL) and saturated NaCl (50 mL). The organic layer 
was dried (Na2SO4) and concentrated under vacuum. The residue was dissolved in 1 mL of EtOH 
and the solution was heated at 50 oC for 10 min under N2. The resulting solid was filtered and 
washed with EtOH (2 × 10 mL). The filtrate was concentrated under vacuum and subjected to 
chromatography (using silica gel pre-treated with 3-hydroxy-2-methyl-4-pyrone) eluting with 20% 
EtOAc/hexane to afford the isoindoline-1,3-dione 11 (266 mg, 18%) as a yellow solid, mp 211-212 
oC. 1H NMR (DMSO-d6): δ; 11.0 (s, H), 7.53 (dd, 8.3, 7.4 Hz, 1H), 7.13 (d, J = 8.6 Hz, 2H), 6.97
(d, J = 8.5 Hz, 2H), 6.93 (d, J = 7.01 Hz, 1H), 6.83 (d, J = 8.6 Hz, 2H), 6.50 (t, J = 6.2 Hz, 1H), 
3.97 (t, J = 4.4 Hz, 2H), 3.89 (t, J = 4.4 Hz, 2H), 3.25 (q, J = 6.7 Hz, 2H), 2.60 (t, J =7.4 Hz, 2H), 
1.84 (quintet, J = 7.3 Hz, 2H), 0.92 (s, 9H), 0.12 (s, 6H); 13C NMR (DMSO-d6): δ; 170.8, 168.7,
156.1, 145.6, 135.3, 132.7, 128.6, 115.8, 113.7, 110.1, 109.2, 68.4, 61.1, 40.7, 29.9, 25.2, 





4-((3-(4-(2-Hydroxyethoxy)phenyl)propyl)amino)isoindoline-1,3-dione (12).  A solution of the 
2-hydroxyethoxysilyl ether (0.22 g, 0.48 mmol) in 7 mL of THF was stirred under N2 at 23 oC and 
1.0 M TBAF in THF (0.95 mL, 0.96 mmol) was added.  When TLC analysis indicated the complete 
consumption of the silyl ether, de-ionized water (5.0 mL) was added and the THF was evaporated 
under vacuum.  The crude mixture was extracted with ethyl acetate (3 × 40 mL) and the combined 
organic layers were washed with saturated NaCl (50 mL), dried (Na2SO4), and concentrated under 
vacuum. The product was purified by column chromatography (using silica gel pre-treated with 3-
hydroxy-2-methyl-4-pyrone) eluted with 20% EtOAc/hexane to afford the isoindoline-1,3-dione 
12 (127 mg, 78%) as a yellow solid, mp 165-166 oC. IR; 1753, 1710, 1377, 1149 cm-1; 1H NMR 
(DMSO-d6): δ 10.9 (s, 1H), 7.51 (dd, J = 8.4, 7.3 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 6.95 (d, J = 
8.4 Hz, 1H), 6.93 (d, J = 7.2 Hz, 1H), 6.84 (d, J = 8.6 Hz, 2H), 6.50 (t, J = 5.9 Hz, 1H), 4.83 (t, J 
= 5.5 Hz, 1H), 3.94 (t, J = 5.2, Hz 2H), 3.69 (q, J = 5.2 Hz, 2H), 3.26 (q, J = 6.6 Hz, 2H), 2.60 (t, 
J = 7.5 Hz, 2H), 1.85 (quintet, J = 7.2 Hz, 1H); 13C NMR (DMSO-d6): δ 171.1, 168.9, 156.5, 
145.8, 135.5, 133.2, 132.7, 128.8, 116.0, 113.9, 110.3, 109.4, 68.9, 59.2, 40.9, 31.0, 30.1. 




4-(Hydroxymethyl)benzaldehyde (19). A 100-mL round-bottomed flask was charged with 
terephthalaldehyde 18 (1.34 g, 7.66 mmol) in 10 mL of MeOH under N2. The solution was cooled 
to 0 °C, NaBH4 (72 mg, 1.92 mmol) was added portion-wise over a 5-min period. The mixture was 
gradually warmed to 23 oC and stirred for 5 h.  After 5 h, the reaction was deemed completed at 
which time, the solvent was removed and the residue was taken up with DCM and transferred to a 







(Na2SO4).  The product was purified by silica gel chromatography using 20% ether/hexane to yield 
the hydroxyaldehyde 19 (1.04 g, 75%) as a colorless oil. IR: 3402, 1691, 1606, 1579,  
1211 cm-1; 1H NMR (CDCl3): δ 10.01 (s, 1H), 7.89 (dd, J = 6.6, 1.6 Hz, 2H),  7.55 (d, J = 8.1 Hz, 
2H), 4.81 (s, 2H), 1.85 (br s, 1H); 13C NMR: (CDCl3): δ 192.0, 147.7, 135.7, 130.0, 126.9, 64.6. 
4-(((tert-Butyldimethylsilyl)oxy)methyl)benzaldehyde (20). A stirred solution of  
4-(hydroxymethyl)benzaldehyde (19, 1.15 g, 8.5 mmol) in DMF (10 mL) was cooled to 0 ˚C under 
N2 and imidazole (1.16 g, 16.9 mmol) was added.  The resulting solution was stirred for 20 min 
and TBS chloride (1.53 g, 10.2 mmol) as a solution in DMF (10 mL) was added dropwise over a 
period of 15 min. The reaction mixture was warmed to 23 oC and stirred until TLC analysis 
indicated the complete absence of the phenol.  The crude reaction was poured into water (50 mL), 
extracted with ether (3 × 40 mL), and the combined organic layers were washed with saturated 
NaCl (50 mL).  The combined organic layers were dried (Na2SO4) and concentrated under vacuum. 
The crude product was purified by column chromatography to afford 4-(((tert-
butyldimethylsilyl)oxy)methyl)benzaldehyde 20 (1.73 g, 82%) as a colorless oil. IR: 1703, 1610, 
1466, 913 cm-1; 1H NMR (CDCl3): δ 10.00 (s, 1H), 7.86 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 8.1 Hz, 
2H), 4.82 (s, 2H), 0.96 (s, 9H), 0.12 (s, 6H); 13C NMR (CDCl3): δ 192.1, 148.7, 135.3, 129.8, 
126.2, 64.5, 25.9, 18.4, -5.3. 
Ethyl (E)-3-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)acrylate (21).  To a stirred, ice-
cold solution of triethylphosphonoacetate (1.42 mL, 7.14 mmol) in THF (10 mL) was added a  60% 
dispersion of NaH in mineral oil (286 mg, 7.14 mmol) and the reaction was stirred for 15 min. To 
the resulting tan solution was added dropwise 4-(((tert-
butyldimethylsilyl)oxy)methyl)benzaldehyde (20 1.5 g, 6.0 mmol) in THF (15 mL) and the mixture 
was warmed to 23 oC.  After the TLC analysis indicated the complete absence of starting material, 
cooled the reaction mass and quenched by dropwise addition of ice-cold water.  The product was 





(15 mL), dried (Na2SO4) and evaporated to afford the acrylate 21, (1.82 g, 97%) as a colorless oil.  
This compound was carried forward without further purification. 
Ethyl 3-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanoate (21a). A solution of ethyl 
(E)-3-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)acrylate 21 (1.82 g, 5.7 mmol) in ethanol 
(25 mL) was flushed twice with N2 and 10% Pd/C (192 mg, 50% wet) was added.  The reaction 
was stirred at room temperature under H2 (1 atm) for 18 h, then filtered through Celite, the bed was 
washed with ethanol (2 x 40 mL) and the filtrate was concentrated under vacuum and purified by 
silica gel column chromatography to afford the propanoate ester 21a (1.14 g, 62%) as a colorless 
oil. IR:2856, 1736.5, 1254., 1088 , 914 cm-1; 1H NMR (CDCl3): δ 7.23 (d, J = 8.0 Hz, 2H), 
7.17 (d, J = 8.1 Hz, 2H), 4.71 (s, 2H), 4.13 (q, J =7.1 Hz, 2H), 2.94 (t, J = 5.1 Hz, 2H), 
2.60 (t, J =8.1 Hz, 2H), 1.2.3 (t, J = 7.5 Hz, 3H), 0.94 (s, 9H), 0.09 (s, 6H). 13C NMR 
(CDCl3): δ 179.7, 139.4, 139.2, 128.2, 126.3, 64.8, 60.4, 36.0, 30.7, 25.9, 18.4, 14.2, -5.2 
3-(4-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl)propanal (22). The propanoate ester 21a 
prepared above (1.0 g, 3.1 mmol) was dissolved in DCM (10 mL) and cooled to –78 oC under N2. 
The solution was treated dropwise with 1.5 M solution of DIBAL-H (2.07 mL, 3.1 mmol) in toluene 
over a period of 30 min. Stirring was continued for 2 h at –78 oC until TLC analysis indicated the 
complete conversion of starting material.  The reaction was quenched by dropwise addition of 
methanol (10 mL), followed by dropwise addition of 1 M HCl (15 mL). The aqueous layer was 
separated and extracted with DCM (2 × 50 mL).  All of the combined organic layers were washed 
with saturated NaCl and dried (Na2SO4). Removal of the solvent under reduced pressure afforded 
3-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanal 22, (0.96 g, 99%) as a colorless oil. 
IR: 1725, 1250, 913cm-1 ; 1H NMR (CDCl3): δ 9.82 (t, J = 1.3 Hz, 1H), 7.26 (d, J = 7.8 Hz, 
2H), 7.14 (d, J = 8.1 Hz, 2H), 4.71 (s, 2H), 2.95 (t, J = 7.6 Hz, 2H), 2.8 (t, J = 7.9, 2H), 
0.94 (s, 9H), 0.09 (s, 6H); 13C NMR (CDCl3): δ 201.7, 166.8, 139.5, 138.9, 128.1, 126.4, 
128.1, 126.4, 64.7, 45.4, 27.8, 25.9, -5.2. 
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4-((3-(4-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl)propyl)amino)isoindoline-1,3-dione 
(23).  To a solution of  3-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanal (22, 0.96 g, 
3.44 mmol) in DMF (1.5 mL) was added AcOH (0.8 mL) and the solution was stirred for 10 min. 
To this reaction mixture, 4-aminophthalimide 6 (0.28 g, 1.72 mmol) was added and stirring was 
continued at 23 oC for 1 h.  An additional 1 mL of DMF was added bringing the volume to 2.5 mL. 
The reaction was cooled to 0 oC and NaBH(OAc)3 (1.13 g, 5.16 mmol) was added portion-wise to 
the reaction. Stirring was continued at this temperature for 30 min, and the reaction was gradually 
warmed to 23 oC and stirred for 18 h.  The crude reaction mixture was poured into de-ionized water, 
extracted with EtOAc (3 × 75 mL) and the combined organic layers were washed with saturated 
NaHCO3 (2 × 50 mL) and saturated NaCl (50 mL). The organic layer was dried (Na2SO4) and 
concentrated under vacuum. The residue was dissolved in 1 mL of EtOH and the solution was 
heated at 50 oC for 10 min under N2. The resulting solid was filtered and washed with EtOH (2 × 
10 mL). The filtrate was concentrated under vacuum and subjected to chromatography (using silica 
gel pre-treated with 3-hydroxy-2-methyl-4-pyrone) eluting with 20% EtOAc/hexane to afford the 
isoindoline-1,3-dione (23 266 mg, 18%) as a yellow solid, mp 211-212 oC. 1H NMR (DMSO-d6):
δ 10.93 (s, 1H), 7.51 (dt, J = 8.2, 6.1 Hz, 1H), 7.22 (d, J = 8.2 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 
6.96 (d, J = 8.5 Hz, 1H), 6.92 (d, J = 7.1 Hz, 1H), 4.66 (s, 2H), 3.26 (t, J = 6.6 Hz, 2H), 6.52 (t, J 
= 5.8 Hz, 1H), 2.64 (t, J = 7.7 Hz, 2H), 1.86 (quintet, J = 7.5 Hz, 2H), 0.88 (s, 9H), 0.06 (s, 6H); 
13C NMR (DMSO-d6): δ 171.9, 169.8, 146.7, 140.5, 139.1, 136.3, 128.6, 128.5, 126.7, 111.3,
110.3, 64.6, 41.8, 32.5, 30.8, 26.3, -4.7. 
4-((3-(4-(Hydroxymethyl)phenyl)propyl)amino)isoindoline-1,3-dione (24).  A solution of 4-
hydroxymethyl silyl ether 23 (0.27 g, 0.63 mmol) in 7 mL of THF was stirred under nitrogen at 23 
oC and 1.0 M TBAF in THF (1.25 mL 1.25 mmol) was added.  When TLC analysis indicated the 
complete conversion of the silyl ether, de-ionized water (5.0 mL) was added and the THF was 





combined organic layers were washed with saturated NaCl (50 mL), dried (Na2SO4), concentrated 
under vacuum. The crude product was purified by column chromatography (using silica gel pre-
treated with 3-hydroxy-2-methyl-4-pyrone) eluting with 20% EtOAc/hexane to afford the 
isoindoline-1,3-dione 24 (155 mg 79%) as a yellow solid, mp 131-132 oC. 1H NMR (DMSO-d6): δ 
10.9 (s, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.23 (d, J = 7.9 Hz, 2H), 7.18 (d, J = 7.9 Hz, 2H), 6.97 (d, J 
= 8.5 Hz, 1H), 6.93 (d, J = 7.1 Hz, 1H) 6.52 (t, J = 5.7 Hz, 1H),  5.09 (t, J = 5.7 Hz, 1H), 4.46 (d, 
J = 5.7 Hz, 2H)  3.28 (q, J = 6.6 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 1.87 (quintet, J = 7.3 Hz, 2H); 
13C NMR (DMSO-d6): δ 170.2, 168.7, 14.6, 139.4, 139.1, 135.3, 132.9, 127.3, 126.0, 155.8, 110.2, 
109.2, 62.1, 40.7, 31.4, 29.8. 





3-(Hydroxymethyl)benzaldehyde (26). A 100-mL round-bottomed flask was charged with 
isophthalaldehyde 25 (5.0 g, 37.31 mmol) in 30 mL of MeOH under N2. The solution was cooled to 
0 °C, NaBH4 (295 mg, 7.8 mmol) was added portion-wise over a 5 min period. The mixture was 
gradually warmed to 23 oC and stirred for 5 h.  After 5 h, the reaction was deemed completed (by 
TLC) at which time, the solvent was removed and the residue was taken up with DCM and 
transferred to a separatory funnel. The organic layer was washed with H2O (25 mL), NaCl (25 mL) 
and dried over (Na2SO4).  The product was purified by silica gel chromatography using 20% 
ether/hexane to yield the hydroxyaldehyde (26, 3.42 g, 70%) as a colorless oil. IR: 3425, 2923, 
2736, 1697, 1600 cm-1; 1H NMR (CDCl3): δ 10.08 (s, 1H), 7.90 (d, J = 0.5 Hz, 1H), 7.82 (dt, J = 
7.6 Hz, 1H), 7.66 (dd, J = 7.6, 0.5 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 4.80 (s, 2 H); 13C NMR: 







3-(((tert-butyldimethylsilyl)oxy)methyl)benzaldehyde (27) A stirred solution of 3-
(hydroxymethyl)benzaldehyde (26, 1.92 g, 14.6 mmol) in DMF (15 mL) was cooled to 0 ˚C under 
N2 and imidazole (2.01 g, 29.3 mmol) was added.  The resulting solution was stirred for 20 min 
and TBS chloride (2.65 g, 17.6 mmol) as a solution in DMF (15 mL) was added dropwise over a 
period of 15 min. The reaction mixture was warmed to 23 oC and stirred until TLC analysis 
indicated the complete absence of the phenol.  The crude reaction was poured into water (50 mL), 
extracted with ether (3 × 40 mL), and the combined organic layers were washed with saturated 
NaCl (50 mL).  The combined organic layers were dried (Na2SO4) and concentrated under vacuum. 
The crude product was purified by column chromatography to afford 3-(((tert-
butyldimethylsilyl)oxy)methyl)benzaldehyde (27, 3.30 g, 90%) as a colorless oil. IR: 2856 , 2720, 
1703, 1591, 1144, 1466, 1103, 1255, 1080 cm-1; 1H NMR (CDCl3): δ 10.0 (s, 1H), 7.83 (d, J = 6.6 
Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.51 (t, J = 7.6 Hz, 1H), 4.81 (s, 2H), 
0.95 (s, 9H), 0.12 (s, 6H); 13C NMR; 192.5, 142.7, 136.4, 132.1, 128.9, 128.4, 127.2, 64.3, 25.9, 
18.4, -5.3. 
Ethyl (E)-3-(3-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)acrylate (28) To a stirred, ice-cold 
solution of triethylphosphonoacetate (2.84 mL, 14.3 mmol) in THF (10 mL) was added a 60% 
dispersion of NaH in mineral oil (572 mg, 14.3 mmol) and stirred for 15 min. To the resulting tan 
solution was added dropwise TBS protected 3-(((tert-butyldimethylsilyl)oxy)-
methyl)benzaldehyde (27, 3.0 g, 12.0 mmol) in THF (15 mL) and the mixture was warmed to 23 
oC.  After the TLC analysis indicated the complete absence of starting material, the reaction mixture 
was cooled and quenched by dropwise addition of ice-cold water.  The product was extracted into 
ether (2 × 25 mL), washed the organic layer with saturated NaCl (15 mL), dried and evaporated to 






Ethyl 3-(3-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanoate (28a) A solution of ethyl 
(E)-3-(3-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)acrylate (28, 2.80 g, 8.8 mmol) in ethanol 
(25 mL) was flushed twice with N2 and 10% Pd/C (320 mg, 50% wet) was added.  The reaction 
was stirred at room temperature under H2 (1 atm) for 18 h,  and then filtered through a Celite®. The 
bed was washed with ethanol (2 × 40 mL) and the filtrate was concentrated under vacuum and 
purified by silica gel column chromatography to afford the propanoate ester (28a) (2.40 g, 84%) as 
a colorless oil. IR: 1735, 1591, 1372, 1253, 1158 cm-1; 1H NMR: (CDCl3): δ 7.20 (t, J = 7.8 Hz, 
1H), 7.09 (d, J = 7.6 Hz, 1H), 7.02 (dd, J = 7.8, 4.9 Hz, 1H) 4.72 (s, 2H), 4.12 ( dq, J = 6.3, 0.8 
Hz,, 2H) 2.93 (t, J = 7.5 Hz, 2H), 2.61 (t, J =7.6 Hz, 2H), 1.24( t, J = 6.7 Hz, 3H) 0.94 (s, 9H), 0.10 
(s, 6H);13C NMR; (CDCl3): δ 173.0, 141.6, 140.5, 128.4, 126.9, 126.0, 124.0, 65.0, 60.4, 35.9, 
30.9, 25.9, 14.2, -5.2. 
3-(3-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl)propanal (29). The propanoate ester 28a 
prepared above (1.4 g, 5.03 mmol) was dissolved in DCM (10 mL) and cooled to –78 oC under N2. 
The solution was treated dropwise with a 1.5 M solution of DIBAL-H (3.36 mL, 5.03 mmol) in 
toluene over a period of 30 min. Stirring was continued for 2 h at –78 oC until TLC analysis 
indicated the complete conversion of starting material.  The reaction was quenched by drop-wise 
addition of methanol (10 mL), followed by the drop-wise addition of 1 M HCl (15 mL). The 
aqueous layer was separated and extracted with DCM (2 × 50 mL).  All of the combined organic 
layers were washed with saturated NaCl and dried (Na2SO4). Removal of the solvent under reduced 
pressure afforded 3-(3-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanal (29, 1.20g, 89%) as 
a colorless oil. This compound was carried forward without further purification. 
4-((3-(4-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl)propyl)amino)isoindoline-1,3-dione 
(30).  To a solution of 3-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanal (29, 1.20 g, 4.32 
mmol) in DMF (1.5 mL) was added AcOH (0.8 mL) and the solution was stirred for 10 min. To 
this reaction mixture, 4-aminophthalimide (6, 0.35g, 2.16 mmol) was added and stirring was 
29 
continued at 23 oC for 1 h.  An additional 1 mL of DMF was added bringing the volume to 3.3 mL. 
The reaction was cooled to 0 oC and NaBH(OAc)3 (1.42 g, 6.50 mmol) was added portion-wise to 
the reaction. Stirring was continued at this temperature for 30 min, and then the reaction was 
gradually warmed to 23 oC and stirred for 18 h.  The crude reaction mixture was poured into de-
ionized water, extracted with EtOAc (3 × 75 mL) and the combined organic layers were washed 
with saturated NaHCO3 (2 × 50 mL) and saturated NaCl (50 mL). The organic layer was dried 
(Na2SO4) and concentrated under vacuum. The residue was dissolved in 1 mL of EtOH and the 
solution was heated at 50 oC for 10 min under N2. The resulting solid was filtered and washed with 
EtOH (2 × 10 mL). The EtOH solution was concentrated under vacuum and subjected to 
chromatography (using silica gel pre-treated with 3-hydroxy-2-methyl-4-pyrone) eluted with 20% 
EtOAc/hexane to afford the isoindoline-1,3-dione 30 (385 mg, 21%) as a yellow solid, mp 223-224 
oC. This compound was carried forward without further purification 
4-((3-(3-(Hydroxymethyl)phenyl)propyl)amino)isoindoline-1,3-dione (31).  A solution of 3-
hydroxymethyl silyl ether 30 (0.37 g, 0.88 mmol) in 7 mL of THF was stirred under nitrogen at 23 
°C and 1.0 M TBAF in THF (1.75 mL, 1.75 mmol) was added.  When TLC analysis indicated the 
complete conversion of the silyl ether, de-ionized water (5.0 mL) was added and the THF was 
evaporated under vacuum. The mixture was extracted with ethyl acetate (3 × 40 mL) and the 
combined organic layers were washed with saturated NaCl (50 mL), dried (Na2SO4) and 
concentrated under vacuum. The crude product was purified by column chromatography (using 
silica gel pre-treated with 3-hydroxy-2-methyl-4-pyrone) eluted with 20% EtOAc/hexane to afford 
the isoindoline-1,3-dione 31 (121 mg 72%) as a yellow solid mp 147-149 oC. IR (nujol); 3378, 1758 
1623, 1213, 972 cm-1 ; 1H NMR (DMSO-d6): δ 10.93 (s,1H), 7.53 (t, J = 7.7 Hz, 1H), 7.25 (t, J =
7.5 Hz, 1H), 7.15 (s, 1H), 7.12 (d, J = 7.6 Hz, 1H), 7.09 (d, J = 7.4 Hz, 1H), 6.98 (d, J = 8.5 Hz, 
1H), 6.92 (d, J = 7.1 Hz, 1H), 6.54 (t, J = 5.9 Hz, 1H), 5.11 (t, J = 5.7 Hz, 2H), 4.45 (d, J = 5.7 





(DMSO-d6): δ 171.9, 169.8, 146.7, 143.1, 136.4, 134.1, 133.7, 128.5, 127.1, 126.8, 124.5, 116.9, 
111.2, 110.3, 63.4, 41.9, 32.8, 30.8. 
1.6.2 One carbon linker in BfrB/Bfd chemical probes 
 




4-((5-Chloro-2-hydroxybenzyl)amino)isoindoline-1,3-dione(34). To a solution of 5-
chlorosalicylicaldehyde (33, 0.52 g, 3.34 mmol) in DMF (1.5 mL) was added AcOH (0.8 mL) and 
the solution was stirred for 10 min. To this reaction mixture, 4-aminophthalimide 6 (0.27 g, 1.67 
mmol) was added and stirring was continued at 23 oC for 1 h. An additional 1 mL of DMF was 
added bringing the volume to 3.3 mL. The reaction was heated to 90 oC for 2 h, and then cooled to 
room temperature. NaBH(OAc)3 (1.1 g, 5.01 mmol) was added portion-wise to the reaction at 0 oC. 
Stirring continued at this temperature for 30 min, and then the reaction was gradually allowed to 
attain 23 oC and stirred for 18 h.  The crude reaction mixture was poured into de-ionized water, 
extracted with EtOAc (3 × 75 mL), and the combined organic layers were washed with NaHCO3 
(2 × 50 mL) and NaCl (50 mL). The organic layer was dried (Na2SO4) and concentrated under 
vacuum. The residue was dissolved in 1 mL of EtOH and the solution was heated at 50 oC for 10 
min under N2. The resulting solid was filtered and washed with EtOH (2 × 10 mL). The EtOH 
solution was concentrated under vacuum and subjected to chromatography (using silica gel pre-
treated with 3-hydroxy-2-methyl-4-pyrone) eluted with 20% EtOAc/hexane to afford the 
isoindoline-1,3-dione 34 as an orange solid (210 mg, 58%), mp 235-236 oC. 1H NMR (DMSO-d6): 
δ 10.9 (s, 1H), 10.4 (s, 1H) 7.58 (dd, J = 8.4, 7.2 Hz, 1H ), 7.28 (d, J = 8.4 Hz, 1H), 7.15 (t, J = 8.1 











6.75 (t, J = 6.2 Hz, 1H), 4.55 (d, J = 6.2 Hz, 2H); 13C NMR (DMSO-d6): δ 172.0, 169.7, 157.2, 
146.4, 136.4, 134.5, 130.2, 122.9, 120.5, 117.1, 114.9, 111.7, 110.8, 40.6. 





Ethyl 2-(3-formylphenoxy)acetate (39). To a solution of 3-hydroxybenzaldehyde (38, 1.0 g, 8.2 
mmol) and K2CO3  (1.38 g, 10.0 mmol) in 10 mL of CH3CN was added ethyl bromoacetate (906 
µL, 8.2 mmol) under N2. The mixture was heated at 90 
oC for 4 h. After cooling the reaction mass 
to room temperature, the solution was poured into water and extracted with EtOAc (3 × 50 mL). 
All of the combined organic layers were washed with saturated NaCl and dried over (Na2SO4). 
The solvent was evaporated and the residue was subjected to silica-gel chromatography using 10% 
EtOAc/hexane to afford (1.53 g, 90%) of ethyl 2-(3-formylphenoxy)acetate 39 as a colorless oil. 
IR: 1750, 1695,1587, 1481, 1199, 912 cm-1; 1H NMR (CDCl3): δ 9.97 (s, 1H), 7.52 (dt, J = 8.7, 
7.5, 2.6 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.38 (dd, J = 3.7, 1.1 Hz, 1H); 13C NMR (CDCl3): δ; 
191.8, 168.4, 158.4, 137.8, 130.3, 124.2, 122.1, 112.9, 65.4, 61.6, 14.2. 
Ethyl 2-(3-(hydroxymethyl)phenoxy)acetate(40). A solution of ethyl 2-(3-
formylphenoxy)acetate 39 (1.53 g, 7.4 mmol) in 10 mL of EtOH was treated portion-wise with 
NaBH4 (0.28 g, 7.4 mmol) at 0 oC. The mixture was gradually warmed to room temperature and 
stirred for an additional 30 min. The EtOH was removed under reduced pressure and the residue 
was diluted with water. The aqueous layer was extracted with 100 mL of a 1:1 DCM/ether mixture. 
The organic layer was washed with saturated NaCl and dried (Na2SO4). Removal of the solvent 
afforded ethyl 2-(3-(hydroxymethyl)phenoxy)acetate (40, 0.98 g, 63%) as a colorless oil. IR: 3279, 








= 2.3 Hz, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.83 (dd, J = 8.1, 2.4 Hz, 1 H), 4.66 (d, J = 4.6 Hz, 2H), 
4.63 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H), 1.73 (t, J = 5.6 Hz, 1H); 13C NMR 
(CDCl3): δ; 168.2 158.7, 142.7, 129.7, 120.1, 113.9, 113.1, 65.4, 65.1, 61.4, 14.2. 
Ethyl 2-(3-(((tert-butyldimethylsilyl)oxy)methyl)phenoxy)acetate (41) A stirred solution of 
ethyl 2-(3-(hydroxymethyl)phenoxy)acetate (40, 0.98 g, 4.7 mmol) in DMF (10 mL) was cooled to 
0 oC under N2 and imidazole (0.63 g, 9.3 mmol) was added.  The resulting solution was stirred for 
20 min and the TBS chloride (0.84 g, 5.6 mmol) as a solution in DMF (10 mL) was added dropwise 
over a period of 15 min. The reaction mixture was warmed to room temperature and stirred until 
TLC analysis indicated the complete absence of the phenolic compound. The crude reaction was 
poured into water (50 mL), extracted with ether (3 × 40 mL), and the combined organic layers were 
washed with saturated NaCl (50 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under vacuum. The crude product was purified by column chromatography to afford 
ethyl 2-(3-(((tert butyldimethylsilyl)oxy)methyl)phenoxy)acetate (40 ,1.24 g, 83%) as a colorless 
oil. IR: 1762, 1739, 1593, 1468, 1560, 1203, 1164, 1083 cm-1; 1H NMR (CDCl3): δ 7.24 (d J = 7.9 
Hz, 1H), 6.94 (t, J = 2.5 Hz, 2H), 6.78 (dd, J = 8.2, 2.5 Hz, 1H), 4.71 (s, 2H), 4.62 (s, 6H); 13C 
NMR (CDCl3): δ 169.5, 158.4, 143.8, 129.8, 119.7, 113.6, 112.6, 65.9, 61.8, 26.4, 18.9, 14.6, -4.8. 
1.6.3 Anticancer Agents 
N-(4-(2-Methyl-4-oxopentan-2-yl)thio)phenyl)acetamide (48). To a stirred solution of 
acetamidothiophenol 46 (25.0 g, 149.7 mmol) in dry chloroform (200 mL) was added triethylamine 
(21.0 mL, 149.7 mmol), followed by addition of mesityl oxide 47 (17.0 mL, 149.7 mmol). The 
resulting slurry was heated to reflux (bath temperature 70 oC). Two additional portions of 
triethylamine (10.5 mL, 74.5 mmol) and mesityl oxide (8.6 mL, 74.5 mmol) were added at regular 
intervals of 4 h, and the resulting solution was refluxed for 16 h after the final addition. The 
resulting reaction mixture was cooled, filtered through Celite and washed with chloroform (2 × 50 





dried (MgSO4), and concentrated under vacuum to give a yellow oil. The crude reaction mixture 
was then purified by silica gel column chromatography and eluted with DCM:ethyl acetate (1:1) to 
afford 48 (27.8 g, 70%) as a pale yellow solid, mp 49-51 oC. IR: 3310, 1699, 1676 cm-1; 1H NMR 
(CDCl3): δ 7.90 (br s, 1H), 7.53 (d, 1H, J = 8.8 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 2.65 (s, 2H), 2.19 
(s, 3H), 2.15 (s, 3H), 1.36 (s, 6H); 13C NMR (CDCl3): δ 206.9, 168.6, 139.0, 138.3, 126.2, 119.6, 
54.3, 47.0, 32.1, 28.0, 24.5. 
N-(4-((4-Hydroxy-2,4-dimethylpentan-2-yl)thio)phenyl)acetamide (49). To a stirred solution of 
methyllithium in ether (198 mL, 316.5 mmol, 1.6 M) in tetrahydrofuran (300 mL) at -50 oC was 
added dropwise 48 (28 g, 105.5 mmol) in tetrahydrofuran (200 mL) over 30-45 min. The reaction 
mixture formed a white precipitate, which was slowly warmed to room temperature over a period 
of 3 h and stirred at this temperature for 1 h. The reaction mass was then cooled to 0 oC, and the 
mixture was quenched by dropwise addition to ice water (150 mL). After adjusting the solution to 
pH 6-7 by addition of 6 M aqueous HCl, the solution was extracted with ethyl acetate (2 × 250 
mL). The combined organic extracts were washed with saturated NaCl (1 × 150 mL), dried 
(MgSO4), and concentrated under vacuum to afford a dark brown liquid. To the crude mixture was 
added chloroform (60 mL) with cooling to 0 oC for 1 h, which afforded a yellow solid. The solid 
was filtered and dried under vacuum to afford  49 (18 g, 61%) as a pale yellow solid, mp 141-142 
oC. IR: 3400, 3303, 1676 cm-1; 1H NMR (CDCl3): δ 7.68 (br s, 1H), 7.52 (m, 4H), 3.50 (br s, 1H), 
2.19 (s, 3H), 1.77 (s, 2H), 1.34 (s, 6H), 1.33 (s, 6H); 13C NMR (CDCl3): δ 168.4, 138.8, 138.1, 
126.3, 119.6, 72.0, 52.0, 49.2, 32.2, 30.8, 24.6. 
N-(2,2,4,4-Tetramethylthiochroman-6-yl)acetamide (50). To a stirred solution of 49 (18 g, 63.9 
mmol) in chlorobenzene (125 mL) at room temperature was added portion-wise anhydrous 
aluminum chloride (10.2 g, 76.7 mmol) over a period of 45 min, and reaction mixture was refluxed 
for 90 min. The reaction mixture was cooled to 23 oC and quenched with ice cold water (150 mL) 
to give a thick suspension. The solid was removed by filtration through Celite and washed with 
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ethyl acetate (2 × 100 mL). The layers were separated, and the aqueous layer was extracted with 
additional ethyl acetate (2 × 100 mL). The combined organic extracts were washed with saturated 
NaCl, dried (MgSO4), and concentrated under vacuum to give a yellow oil. The crude product was 
purified on a silica gel column using hexanes:ethyl acetate (1:1) to afford the product  50 (15.0 g, 
89%) as a pale yellow solid, mp 105-107 oC. IR: 3295, 1662 cm-1; 1H NMR (CDCl3): δ 7.60 (br s, 
1H), 7.27 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 8.2, 2.3 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 2.16 (s, 3H), 
1.92 (s, 2H), 1.39 (s, 6H), 1.35 (s, 6H); 13C NMR (CDCl3): δ 168.3, 143.4, 135.1, 128.4, 128.2, 
118.7, 118.2, 54.4, 42.0, 35.7, 32.4, 31.4, 24.4. 
2,2,4,4-Tetramethylthiochroman-6-amine hydrochloride (51). To a stirred solution of 50 (15.0 
g, 56.9 mmol) in methanol (75 mL) was added 6 M aqueous HCl (75 mL). The reaction mixture 
was heated to 90 oC for 1 h, followed by cooling to room temperature. The reaction was 
concentrated to 1/4 of its initial volume. The resulting mixture was cooled to 0 oC and maintained 
at this temperature for 1 h to yield a solid. This material was filtered and dried under vacuum to 
afford  51 as a white solid (14.0 g, 95%), mp 208-209 oC. IR: 2922, 2853 cm-1; 1H NMR (DMSO-
d6): δ 10.08 (s, 2H), 7.48 (s, 1H), 7.22 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1H), 1.94 (s, 2H), 
1.42 (s, 6H), 1.40 (s, 6H); 13C NMR (DMSO-d6): δ 144.2, 132.0, 130.0, 129.1, 122.0, 121.2, 53.5, 
42.6, 35.8, 32.6, 31.6.  
Phenyl 3-methylbut-2-enoate (54). To an oil-free suspension of NaH (1.34 g, 56.0 mmol) in 
anhydrous THF (20 mL) at 0 
o
C (ice bath) was added over a 5-min period with stirring a solution 
of phenol 52 (5.0 g, 53 mmol) in THF (55 mL). The solution was stirred for 10 min and treated 
with a solution of 3-methylbut-2-enoyl chloride 53 (7.0 g, 59 mmol) in THF (25 mL) over a 5-min 
period at 0 oC, and was then allowed to warm to 23 oC for 3 h. The white suspension was transferred 
to a separatory funnel containing water (150 mL) and acetic acid (1 mL) and was gently shaken. 
The mixture was extracted with ether (150 mL), and the extract was washed with saturated NaCl 





purified on a 40-cm x 2.5-cm silica gel column eluted with 10% ether in hexanes to give 54 (8.4 g, 
89%) as a colorless oil. IR: 1738, 1653 cm-1; 1H NMR (CDCl3): δ d 7.38 (t, J = 7.9 Hz, 2H), 7.20 
(t, J = 7.8 Hz, 1H), 7.10 (d, J = 8.0 Hz, 2H), 5.91 (m, 1H,), 2.22 (d, J = 1.8 Hz, 3H), 1.96 (d, J = 
1.8 Hz, 3H); 13C NMR (CDCl3): δ 164.9, 159.9, 150.7, 129.3, 125.5, 121.8, 115.3, 27.6, 20.5.  
4,4-Dimethylchroman-2-one (55). Into a 500-mL, three-necked, round-bottomed flask equipped 
with a stir bar, an addition funnel and a condenser (drying tube) was placed DCM (164 mL) to 
which was added AlCl3 (9.87 g, 74.0 mmol). The resulting suspension was stirred and cooled to  
0 oC , and a solution of 54  (7.4 g, 42.0 mmol) in DCM (40 mL) was added dropwise. The reaction 
was gradually warmed to room temperature, and stirring was continued for 72 h. The resulting 
brown solution was added to a mixture of ice and saturated NaCl, the layers were separated, and 
the aqueous layer was extracted with DCM (100 mL). The combined organic layers were washed 
with saturated NaCl (2 × 75 mL), dried (MgSO4), filtered, and concentrated to give a brown oil, 
which was purified by silica gel chromatography using 10% ether in hexanes to give 55 (5.00 g, 
68%) as a colorless oil. IR: 1769 cm-1; 1H NMR (CDCl3): δ 7.33 (dd, J = 7.4, 1.7 Hz, 1H), 7.25 
(td, J = 7.9, 1.7 Hz, 1H), 7.15 (td, J = 7.5, 1.4 Hz, 1H), 7.05 (dd, J= 8.0, 1.4 Hz, 1H), 2.62 (s, 2H, 
CH2), 1.36 (s, 6H, 2 CH3); 13C NMR (CDCl3): δ 168.1, 150.6, 131.7, 128.2, 124.8, 124.4, 117.1, 
45.6, 33.2, 27.6. 
2-(4-Hydroxy-2,4-dimethylpentan-2-yl)phenol (56). A solution of 55 (2.5 g, 14.2 mmol) in dry 
ether (40 mL) was placed in a 250-mL, three-necked, round-bottomed flask equipped with a stir 
bar, a septum, and a condenser. The solution was cooled to -45 
o C (dry ice/acetonitrile bath), and 
an ether solution of methyllithium (1.6 M, 22.2 mL, 35.5 mmol) was added over 20 min. The 
reaction was stirred for 18 h with gradual warming to room temperature. The reaction was carefully 
poured into a mixture of ice and saturated NH4Cl and shaken. The layers were separated, and the 
aqueous layer was washed with ether (2 × 50 mL). The combined ether layers were washed with 
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saturated NH4Cl and water, dried (MgSO4), filtered, and concentrated under vacuum. The resulting 
oil solidified on standing at room temperature. The solid was triturated with 1% ether in pentane 
and filtered to give 56 (2.72 g, 92%) as a white solid, mp 86-88 °C. IR: 3540, 3259, 1372, 753 cm-
1; 1H NMR (CDCl3): δ 7.29 (dd, J = 7.8, 1.7 Hz, 1H), 7.07 (td, J = 7.7, 1.7 Hz, 1H,), 6.88 (td, 
J=7.5, 1.4 Hz, 1H,), 6.65 (br s, 1H, phenol OH), 6.62 (dd, J = 7.9, 1.4 Hz, 1H), 2.22 (s, 2H, CH2), 
1.74 (br s, 1H, OH), 1.48 (s, 6H, 2CH3), 1.12 (s, 6H, 2CH3); 13C NMR (CDCl3): δ 154.9, 134.4, 
127.8, 127.5, 120.7, 117.5, 73.2, 52.4, 37.5, 31.0, 30.9.  
2,2,4,4-Tetramethylchroman (57) A 100-mL, one-necked, round-bottomed flask was charged 
concentrated phosphoric acid (10 mL). The acid was heated to 100 °C, 56 (2.08 g 10 mmol) was 
added, and the mixture was stirred for 1 h. The crude reaction mixture was cooled, diluted with 
water, and extracted with ether (3 × 25 mL). The combined organic layers were washed with 
saturated NaHCO3 and saturated NaCl, dried (MgSO4),filtered, and concentrated under vacuum. 
The resulting oil was passed through a column of silica gel using hexanes as the eluent to give 57 
(1.81 g, 95%) as a colorless oil. IR: 1367, 753 cm-1; 1H NMR (CDCl3): δ 7.19 (dd, J = 7.7, 1.4 Hz, 
1H), 6.99 (td, J = 7.9, 1.4 Hz, 1H) , 6.83 (t, J = 7.5 Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 1.76 (s, 2H, 
CH2), 1.28 (s, 6H, 2CH3), 1.27 (s, 6H, 2CH3); 13C NMR (CDCl3): δ 152.5, 131.5, 127.0, 126.8, 
120.6, 117.9, 74.3, 49.3, 32.8, 30.8, 28.6.  
2,2,4,4-Tetramethyl-6-nitrochroman and 2,2,4,4-tetramethyl-8-nitrochroman A 25-mL, 
three-necked, round-bottomed flask equipped with a magnetic stirrer, an addition funnel, and a 
nitrogen inlet was charged with 57 (1.00 g, 5.3 mmol) and freshly distilled acetic anhydride (1 mL). 
The solution was cooled to -15 °C (ice/methanol bath), and a cold solution of concentrated nitric 
acid (577 μL) in acetic anhydride (1 mL) was added dropwise over 15 min. The reaction was stirred 
at -5 °C for 30 min and then diluted with DCM and washed with saturated NaHCO3. The NaHCO3 





water and saturated NaCl, dried (MgSO4), filtered, and concentrated under vacuum to give 1.2 g of 
the crude product which was taken directly to the reduction step. 
2,2,4,4-Tetramethylchroman-6-amine (58). A 100-mL-round bottomed flask, equipped with a 
condenser and stir bar was charged with the nitro compound prepared above. To this solution, Fe 
powder (0.86 g, 15.3 mmol) and NH4Cl (0.27 g, 5.10 mmol) were added in a 4:1 mixture of 
EtOH/H2O. The mixture was heated to 80
 o
C for 3 h, and then it was filtered through Celite®. The 
filter cake was rinsed with NaHCO3 and the aqueous layer was extracted with EtOAc (3 × 50 mL). 
The combined organic layers were washed with saturated NaCl and dried over (Na2SO4). Removal 
of the solvent and purification by silica gel chromatography afforded 58, the 6-isomer as a yellow 
oil (the 8-isomer eluted first) IR: 3435, 3358, 3221, 1627, 1498 cm−1; 1H NMR (CDCl3): δ 6.63 (s, 
1H,), 6.61 (d, J = 7.8 Hz, 1H,), 6.47 (dd, J = 7.8, 2.7 Hz, 1H, ), 3.50 (br s, 2H, NH2), 1.78 (s, 2H), 
1.31 (s, 6H), 1.29 (s, 6H); 13C NMR (CDCl3): δ 145.4, 139.5, 132.3, 118.3, 114.9, 113.4, 73.8, 49.3, 
32.6, 31.0, 28.4. 
6-Isothiocyanato-2,2,4,4-tetramethylthiochroman (59). A 100-mL, one–necked, round 
bottomed flask equipped with a condenser and a stir bar was charged with 2,2,4,4-
tetramethylthiochroman-6-amine (58, 0.258 g, 1 mmol), Et3N (140 μL, 1mmol) and CS2 (604 μL, 
10 mmol) under N2.  After stirring for 10 minutes, 5 mL of ethanol was added, and stirring was 
continued for 1 h. The solution was then cooled to 0 oC, and solutions of di-tert-butyl dicarbonate 
(0.20 g, 0.9 mmol) and 4-dimethylaminopyridine (4 mg, 3 mol%) in 1 mL of ethanol were added 
consecutively.  The resulting mixture was gradually warmed to room temperature over 30 min. The 
solvent was then removed on the rotary evaporator to provide 59 (0.24 g, 90%) as a thick yellow 
oil.  IR: 2961, 2920, 2113 (NCS), 1470 cm−1; 1H NMR (CDCl3): δ 7.32 (d, J= 2.2 Hz, 1H), 7.07 
(d, J = 8.31 Hz, 1H), 6.92 (dd, J = 8.3, 2.2 Hz, 1H), 1.93 (s, 2H), 1.41 (s, 6H), 1.37 (s, 6H); 13C 
NMR (CDCl3) : δ 144.79, 133.5, 129.4, 129.3, 128.0, 124.7, 123.8, 54.3, 42.9, 36.2, 32.8, 32.0.  
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6-Isothiocyanato-2,2,4,4-tetramethylchromane (60). A 100-mL, one–necked, round-bottomed
flask equipped with a condenser and a stir bar was charged 6-isothiocyanato-2,2,4,4-
tetramethylchroman 58 (0.21 g, 1 mmol), Et3N (140 μL, 1.0 mmol) and CS2 (604 μL, 10 mmol) 
under N2.  After stirring for 10 min, 5 mL of ethanol was added, and stirring was continued for 1 h. 
The solution was then cooled to 0 oC, and two separate solutions of di-tert-butyl dicarbonate (0.20 
g, 0.9 mmol) and 4-dimethylaminopyridine (4 mg, 3 mol%) in 1 mL of ethanol were added 
consecutively.  The resulting mixture was gradually warmed to room temperature over 30 min. 
Then the solvent was then removed on the rotary evaporator to provide 60 (0.23 g, 94%) as a thick 
yellow-orange oil. IR: 2971, 2120 (NCS), 1487 cm−1; 1H NMR (CDCl3) : δ 7.15 (d, J = 2.5 Hz, 
1H), 6.96 (dd, J = 8.6, 2.5 Hz, 1H), 6.92 (d, J = 8.6, 1H), 1.82 (s, 2H), 1.36 (s, 6H), 1.33 (s, 6H) ; 
13C NMR (CDCl3): δ 152.4, 150.2, 133.3, 125.0, 123.7, 119.5, 75.6, 49.1, 33.1, 28.9. 
General procedure for the synthesis of carbothioamides (62a-b, 64a-c and 65):A 50-mL, round 
bottomed flask was charged with 61a-b or 63a-c in 5 mL of hot THF under N2.   The resulting 
solution was cooled to 0  °C, and 58 or 60 in 5 mL of hot THF was added dropwise over a 20 min. 
The solution was gradually warmed to room temperature with continued stirring overnight.  Upon 
completion, the solution was concentrated under vaccum, and the residue was taken up in water 
and extracted with EtOAc (3×).  The combined organic layers were washed with brine and dried 
(Na2SO4) and concentrated. The resulting oil was dissolved in an ether/pentane mixture, which 
produced a precipitate of the compounds 62a-b, 64a-c or 65.  
N-2-(4-Nitrophenyl)-N-(2,2,4,4-tetramethylthio-chroman-6-yl)hydrazine-1-carbothioamide
(62a). Tan solid, mp 181-183 °C, (0.142 g, 50%). IR (nujol): 15780, 1356, 1242 cm−1; 1H NMR 
(DMSO-d6): δ 9.90 (s, 2H), 9.19 (s, 1H), 8.16 (d, J = 8.9 Hz, 2H), 7.56 (d, J = 1.2 Hz, 1H), 7.25 
(dd, J = 8.3, 1.7 Hz, 1H), 6.97 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 9.1 Hz, 2H), 1.91 (s, 2H), 1.36 (s, 
6H), 1.32 (s, 6H);  13C NMR (DMSO-d6): δ 154.6, 152.5, 142.3, 139.5, 136.4, 128.6, 127.2, 
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126.3, 124.4, 112.2, 53.9, 42.4 35.9, 32.7, 31.6. Anal. Calcd for C20H24N4O2S2: C, 57.67; H, 
5.81; N, 13.45. Found: C, 57.71; H, 5.92, N, 13.31. 
N-(2,2,4,4-Tetramethylthiochroman-6-yl)-2-(4-(trifluoromethyl)phenyl)hydrazine-1-
carbothioamide (62b). White solid, mp 163-165 °C (0.183 g, 71%). IR (nujol): 1645 cm−1; 1H 
NMR (DMSO-d6): δ 9.83 (s, 1H), 9.78 (s, 1H), 8.60 (s, 1H),  7.61 (d, J = 2.2 Hz, 1H), 7.33 (dd, J 
= 8.4, 2.2 Hz, 1H), 7.58 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 8.5 Hz, 2H), 
1.91 (s, 2H), 1.36 (s, 6H), 1.32 (s, 6H); 13C NMR (DMSO-d6): δ 151.9, 142.7, 136.7, 128.3, 127.1, 
126.7, 126.2 124.3 (q, J = 272.2 Hz)  123.6, 112.9, 53.9, 42.4, 35.7, 32.8, 31.7. Anal. Calcd for 
C21H24F3N3S2: C, 57.38; H, 5.50; N, 9.56. Found: C, 57.15; H, 5.49, N, 9.29. 
2-Nicotinoyl-N-(2,2,4,4-tetramethylchroman-6-yl)hydrazine-1-carbothioamide (64a)
White solid, mp 123-125 °C (0.133 g, 41%). IR (nujol): 1785, 1601 cm−1; 1H NMR (DMSO-d6): δ 
10.70 (s, 1H), 9.69 (s, 2H), 9.10 (d, J= 2.0 Hz, 1H),  8.75 (dd, J = 4.7, 1.7 Hz, 1H), 8.28 (d, J = 
7.9 Hz, 1H) 7.55 (dd, J = 7.8, 4.9 Hz, 1H), 7.29 (s,1H), 7.10 (d, J = 7.2 Hz, 1H) 6.68 (d, J = 8.6 
Hz, 1H), 1.81 (s, 2H), 1.29 (s, 12H); 13C NMR (DMSO-d6): δ 165.3, 151.6, 147.9, 142.9, 136.1, 
134.7, 127.8, 126.9, 126.5, 123.1, 61.5, 42.8, 36.1, 32.5, 31.4. Anal. Calcd for C20H24N4O2S: C, 
62.48; H, 6.29; N, 14.57. Found: C, 62.37; H, 6.29, N, 14.23. 
2-(4-Nitrobenzoyl)-N-(2,2,4,4-tetramethylchroman-6-yl)hydrazine-1-carbothioamide (64b).  
White solid, mp 171-172 °C (0.124 g, 43%). IR (nujol): 1782, 1575, 1354 cm−1; 1H NMR (DMSO-
d6): δ 10.9 (s, 1H), 9.73 (s, 2H), 8.34 (d, J = 8.8 Hz, 2H), 8.16 (d, J = 8.7 Hz, 2H), 7.29 (s, 1H), 
7.11 (dd, J = 8.5, 1.8 Hz, 1H), 6.67 (d, J = 8.6 Hz, 1H), 1.81 (s, 2H), 1.29 (s, 12H); 13C NMR 
(DMSO-d6): δ 178.5, 164.5, 149.5, 138.4, 131.7, 130.5, 129., 123.4, 116.8, 74.2, 48.2, 32.5, 30.6, 
28.1. Anal. Calcd for C21H24N4O4S: C, 58.86; H, 5.65; N, 13.08. Found: C, 58.77; H, 5.71, N, 13.05. 
N-(2,2,4,4-Tetramethylchroman-6-yl)-2-(4-(trifluoromethyl)benzoyl)hydrazine-1-
carbothioamide (64c). White solid, mp 118-119 °C (0.152 g, 52%). IR (nujol): 1745 cm-1; 
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1H NMR: (DMSO-d6): δ 10.7 (s, 1H), 9.70 (s, 2H), 8.15 (d, J = 8.2 Hz, 2H), 7.91( d, J = 8.3 Hz, 
2H) 7.29 (s, 1H), 7.12 (dd,  J = 8.6, 2.1 Hz, 1H), 6.69 (d, J = 5.6 Hz, 1H), 1.81 (s, 2H), 1.30 (s, 
6H), 1.29 (s, 6H) 13C NMR: (DMSO-d6): δ 178.6, 163.2, 156.1, 144.2., 142.9, 138.9, 136.1, 129.5, 
127.1, 125.7, 123.3, 122.7, 119.4 (q, J = 270.2 Hz), 118.8, 113.4, 53.9, 42.4, 40.4, 35.7, 32.7, 31.6. 
Anal. Calcd for C22H22F3N3O2S: C, 58.52; H, 5.36; N, 9.31. Found: C, 58.38; H, 5.47, N, 9.35. 
2-nicotinoyl-N-(2,2,4,4-tetramethylthiochroman-6-yl)hydrazine-1-carbothioamide (65).
White solid, mp 151-153 °C (0.113 g, 55%). IR (nujol): 1778 cm−1; 1H NMR (DMSO-d6): δ 
10.8 (s, 1H), 9.77 (s, 2H), 9.10 (d, J = 2.2 Hz, 1H), 8.75 (dd, J = 4.7, 1.5 Hz, 1H), 8.26 (d, J = 7.9 
Hz, 1H),  7.56 (dd, J = 7.8, 4.9 Hz, 2H), 7.19 (d, J = 7.8 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 1.92 (s, 
2H), 1.37 (s, 6H), 1.33 (s, 6H); 13C NMR (DMSO-d6): δ 177.6, 164.7, 152.4, 148.9, 141.9, 136.2, 
135.7, 135.6, 128.2, 126.9, 126.8, 123.4, 53.5, 41.9, 35.2, 32.3, 31.2. Anal. Calcd for C20H24N4OS4: 
C, 59.97; H, 6.04; N, 13.99. Found: C, 59.78; H, 6.09, N, 13.89. 
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CHAPTER II 
SYNTHESIS OF BIOACTIVE HETEROCYCLIC SCAFFOLDS 
2.1 Introduction 
The need for synthesis and optimization studies to efficiently prepare biologically active 
heterocyclic scaffolds has increased. Synthetic chemists look for the most viable and cost-effective 
routes to simplify the total synthesis of various targets. More importantly, recent efforts in drug 
discovery have amplified the need to develop high atom economy and eco-friendly ways to access 
heterocyclic frameworks. In past years, the use of transition metal catalysts to access carbon-carbon 
bonds has dominated organic chemistry and has been a central topic in the synthesis of heterocyclic 
scaffolds. However, utilizing transition metal catalysts in late-stage drug synthesis requires the use 
of special purification techniques to remove them from the final target. 
Common purification methods such as filtration through Celite or silica gel chromatography may 
not always free the final product of these toxic metals. Therefore, it is crucial to formulate simple, 
transition metal-free methodologies to prepare heterocyclic scaffolds through carbon-carbon bond 
forming reactions. Zolpidem, a sedative, was previously synthesized in a 4-step fashion from 4-
methylacetophenone in 66% yield.38 However, the synthesis of Zolpidem was improved and 
obtained in 96% from 2-aminopyridines and Morita-Bayliss-Hillman acetates of nitroalkenes.39 
Our research group is primarily involved in developing new drug molecules as antibiotic and anti-
cancer candidates. Additionally, we strive to develop cost-effective, high atom economy synthetic 
methodology to important heterocyclic scaffolds such as quinazolinones, dihydroquinolines, 
indoles, naphthyridines, and chromanones. As an extension of this dissertation work, new methods 
have been developed to synthesize, 7-nitro-2-naphthoates, 6-nitro-1,2-dihydroquinolines
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carboxylates, 1,8-naphthyridine carboxylates, and 4-chromanones as well as an efficient synthesis 
of 2-fluoro-5-nitronicotinaldehyde.  
2.1.2  A Mortia-Bayliss-Hillman inspired synthesis of heterocyclic scaffolds  
The Morita-Bayliss Hillman (MBH) reaction has proven to provided access to a wide variety of 
pharmaceuticaly important scaffolds.40 Since it was first introduced in 1941, the scope of the 
reaction has broadened dramatically (Figure 2.1) and its versatility has been exploited extensively 
by synthetic chemists.41-44 
Figure 2.1 Scope of Morita-Bayliss-Hillman Reaction 
The MBH reaction is a carbon-bond forming reaction resulting in allylic alcohols or (MBH adducts) 
from electrophiles and activated alkenes.41-44 The reaction is promoted by the addition of a tertiary 
amine or phosphine catalyst. In addition, these adducts, and their acetates have proven to be 
attractive synthons in building toward more complex molecular frameworks.41-44 Recently, Reddy 
and co-workers published a thorough review on the impact and importance of the MBH reaction in 





access biologically active heterocyclic systems such as imidazopyridines38, isoxazoles43, and 
acridines45 exhibiting anti-malarial activity. 
2.2 Results and discussion.  
2.2.1 Naphthoates, dihydroquinolines carboxylates and naphthyridine carboxylates from 
MBH acetates.  
The current study was pursued with the goal of providing attractive heterocyclic scaffolds from 
MBH acetates.  One of these scaffolds is naphthalene, which is the simplest bicyclic aromatic ring, 







Figure 2.2 Naphthalene containing anticancer agents 
 Some of the methods for the synthesis of naphthalene-containing molecules involve transition 
metal catalysts such as PdCl2, GaCl3 and TiCl4 which may require some type of purification step to 
limit metal contamination in the final products.46-48 Our strategy to prepare highly substituted 
naphthalene containing compounds originated from the MBH reaction between 2-fluoro-5-
nitrobenzaldehyde 6a and ethyl acrylate 7a in the presence of DABCO 8 to afford the desired MBH 



















Scheme 2.1 Reaction rationale toward substituted naphthalenes 
Originally, the reaction was performed at 23 °C using equimolar equivalents of 6a, 7a and 8. 
Extractive work-up and 1H NMR analysis of the product, revealed the presence of 9a. One of the 
goals of this study was to afford a clean conversion of the MBH adducts and minimize purification 
steps enroute to our target compounds. Current methods involve the use of 7a as a solvent and 
reactant, but still require purification by column chromatography.49 More commonly however, the 
reaction is performed in a polar aprotic solvent using an excess of the activated alkene component.50 
This work focused on including electron withdrawing groups at C5 of an aromatic electrophile 
(Figure 2.3), which proved crucial in achieving maximum conversion to the corresponding 
adducts.51
Figure 2.3 Illustration of C5 on electrophiles 
With these guidelines in hand, we were able to broaden the scope of the reaction (Scheme 2.2) and 
synthesize new MBH adducts at 23°C in excellent purity from their respective electrophiles and 

























Scheme 2.2 Reaction scope of MBH adducts 
X Entry Alkene MBH Adduct/ Yield (%) 
NO2 Y=C, 6a 7a, R1=OEt 9a  (97%) 
NO2 Y=C, 6a 7b, R1=OMe 9b (92%) 
NO2 Y=C, 6a   7c, R1=OCF3 9c (82%) 
NO2 Y=C, 6a 7d, R1=CN 9d (80%) 
F Y=C, 6b 7a, R1=OEt 9e (83%) 
F Y=C, 6b 7b, R1=OMe 9f (99%) 
H Y=N, 6c 7a, R1=OEt 9g (99%) 
H Y=N, 6c 7b, R1=OMe 9h (96%) 





























Figure 2.4 Synthesized MBH adducts 
The mechanism of the MBH reaction has been reviewed extensively.39,43-48,52 A plausible 







Figure 2.5 A plausible mechanism for MBH reaction 
In order to furnish our desired naphthalene precursors, the MBH adducts 9a-h were converted to 
their respective acetates. Common acylation methods of MBH acetates include the utilization of 
acetyl chloride or acetic anhydride in dichloromethane with pyridine as a base.40-49 Acylation of 
MBH adducts greatly enhance their reactivity toward Michael reactions.40-49 To our delight, the 
acetylation step proceeded cleanly by simply refluxing the corresponding adducts 9a-h in 2 mL of 













































































9a 9b 9c 9d
9e 9f 9g 9h
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step in our synthesis. Therefore, all acetates were purified by column chromatography after 
extractive work-up furnishing the acetates (Figure 2.5) 10a-h (Scheme 2.3) in 75-95% yield.  
Scheme 2.3 Synthesis of MBH acetates 
Finally, our targeted naphthalene compounds were synthesized via a Michael elimanation-SNAr 
from 10a-h and active methylene compounds, e.g. ethyl cyanoacetate, ethyl nitroacetate and methyl 
phenylsulfonylacetate. The desired 7-nitro-2-naphthoates 11a-c were synthesized (Scheme 2.4) in 
the presence of K2CO3 in 1 mL of DMF in excellent purity after extractive work-up. This was made 
Figure 2.6 MBH acetates 
possible by using electrophiles bearing the fluorine atom at the C2 of the aromatic electrophile. The 
smaller fluorine atom is more reactive toward a SNAr reaction.49,53 This reactivity is enhanced by 
the nitro group para to the fluorine atom. The order of reactivity for a SNAr reaction is as follows: 





























































Scheme 2.4 Synthesis of naphthoates 
In addition to the synthesis of substituted naphthoates, we were able to synthesizee 
dihydroquinolines and naphthyridines from MBH acetates 10a-h (Y=N) and aryl and alkyl amines 









Scheme 2.5 Synthesis of dihydroquinoline and naphthyridine carboxylates 
Previous methods involving the aza-Michael elimanation-SNAr reaction between 10a-h and amine 
components failed to provide the desired heterocyclic compounds without silica gel 
chromatography, even in the presence of excess amine.50-53 In our case, through an acid-base work-
up, any unreacted amine component was washed away, furnishing compounds 12a-f. In the case of 
13, methylamine in water (12.1 M) was used as the solvent and reactant, and led to desired 





















































In summary, we were able to synthesize several bioactive heterocyclic systems by implementation 
of the MBH reaction, in good to excellent yields. The products were formed by a procedure that 
eliminated high temperatures, strong bases, and metal catalysts. Also, all products were obtained 
without the need for column purification, further establishing the versatility and elegance of our 
method.  
2.2.3 Synthesis of 2-fluoro-5-nitronicontinaldehyde 
Pyridines are present in a wide variety of compounds ranging from natural products, vitamins, and 
active pharmaceutical ingredients. The pyridine moiety, though hard to synthesize, is a vital 
scaffold (Figure 2.6) in drug discovery, which is why its synthesis has been so thoroughly 
investigated by orgnanic chemists.54-57 Due to their small molecular size and high stability, 
pyridines can serve as bioisosteres for benzenes, amines and amides.54 Recent procedures for 
pyridine synthesis include reactions between N-oxides and Grignard reagents,55-57 cross-coupling 








Figure 2.7 Anticancer and antimicrobial drugs bearing the pyridine moiety 
This work was directed towards synthesizing an essential pyridine building block that could serve 
as the next pharmaceutically important scaffold. Coincidentally, our group strives to develop 



























synthesis. By preparing 2-fluoro-5-nitronicotinaldehyde 23 from 19 (Scheme 2.6) we have 
simultaneously established a synthetic route to two unknown pyridine compounds and broken 
through the next frontier of accessible scaffolds. 
Scheme 2.6 Synthesis of 2-fluoro-5-nitronicotinaldehyde (23) 
Compound 19 was synthesized in excellent yield according to literature methods.58-59 The 
esterification of 19 was achieved by refluxing in MeOH using a catalytic amount of H2SO4 to 
provide 20 in excellent yield as a white solid. The chlorination sequence of 20 was performed by 
using an excess  of SOCl2 in CHCl3 to afford 21. Several attempts were made to synthesize 22 by 
a reduction-oxidation sequence in the presence of the nitro functional group. Trial experiments with 
LiAlH4, NaBH4 failed in our system. An aromatic nitro group is readily reduced to an amine in the 
presence of LAH. On the other hand ,NaBH4 is not known to be potent enough to efficiently reduce 
aromatic esters. The reduction of 21 to 22, however, was successful achieved by using a slight 
excess of DIBAL-H (1.5 M/PhMe) at -78°C (dry ice/acetone) bath. The hydride reagent was added 
dropwise over a 30-minute period. Failure to maintain the addition rate and low temperature 
resulted in an impurity (mixture of reduced alcohols) that was uncharacterizable by 1H NMR. The 
reaction was quenched by the dropwise addition of a saturated aqueous solution of Rochelle’s salt 
(potassium sodium tartrate solution) at -70°C.17 After extractive work-up and silica gel 
chromatography, the desired aldehyde was furnished as a yellow oil. Displacement of the chlorine 
































compound 23 was obtained as a white solid after purification by column chromatography in 82%. 
The goal of this particular work was to synthesize nicontinaldehyde derivatives that were not 
previously known in the literature. As a result, we were able to synthesize two derivatives, 22 and 
23, which can serve as a starting point for building small molecule libraries or be used as potential 
starting points for future projects.  
2.2.4 Conclusion 
The synthesis of 2-fluoro-5-nitronicotinaldehyde was completed using a four-step sequence. In 
addition, because of the commercial availability of the reagents and starting material, this process 
was inexpensive and could easily be reproduced on a gram scale. Future investigations focusing on 
implementing 2-fluoro-5-nitronicotinaldehyde as a starting point for potential projects is ongoing 
in our group.  
2.2.5 A bismuth (III) trifluoromethanesulfonate catalyzed route to 4-chromonones  
Efficient methods to produce oxygen heterocycles for use as building blocks in natural product and 
drug synthesis is a worthy endeavor.  Among the heterocyclic scaffolds containing oxygen, 4-
chromanones are widely dispersed in nature and constitute valuable substrates for drug synthesis.62-
63 Various derivatives of this system also exhibit a wide range of pharmacological activities such 
as anti-bacterial64, anti-HIV65, anti-cancer66 and anti-fungal64. Common methods for the synthesis 
of 4-chromanones have utilized a wide range of reaction protocols.  One of the first generated 7-
hydroxy-2,2-dimethyl-4-chromanone from highly activated resorcinol with 3,3-dimethylacrylic 
acid in the presence of SbCl3.66 More commonly, a number of chromanone derivatives were 
synthesized from chalcones, via an intramolecular Wittig strategy.67 A more common method 
involved the acylation of o-hydroxyacetophenone with an aromatic acid chloride resulting in an 
aromatic ester, which was treated by base, undergoing a Baker-Venkataraman rearrangement to a 





2-arylchromanoe after a cyclocondensation reaction with acyl compounds.68  Our approach 
involved the reaction of phenols bearing additional activating groups with 3,3-dimethylacrylic acid 
or crotonic acid to give a variety of tetra- and trisubstituted 4-chromanones, respectively. This was 
achieved by utilizing bismuth(III) trifluoromethanesulfonate to catalyze a one-pot conversion 
involving a tandem esterification–Fries rearrangement–oxa-Michael sequence.  
Initially, we attempted the Friedel–Crafts ring closure of phenyl 3,3-dimethylacrylate (24a, X = H) 
to other phenol-derived acrylate esters. Cyclization of 24a is reported to give 4,4-dimethyl-2-
chromanone (25) in >70% yield using 1.7 equiv of aluminum chloride in dichloromethane,35 and 
we have successfully employed this procedure to access drug precursors for one of our projects.34 
Attempts to perform this reaction with esters incorporating more activated aryl groups, however, 
led to mixtures of several products. For example, 24b (X = Me) produced 1-(2-hydroxy-4-
methylphenyl)-3-methyl-2-buten-1-one (26b, 18%) and 2,2,7-trimethyl-4-chromanone (27c, 65%) 







Scheme 2.7. Friedel-Crafts reaction of aryl ester of 3,3-dimethylacrylic acid 
After careful consideration, it was determined that the 4-chromanone product is likely derived from 
a Lewis acid promoted tandem esterification-Fries rearrangement-oxa Michael reaction. As a 
AlCl3, CH2Cl2, 0 –> 23 oC
a: X = H. 70% O O
AlCl3, CH2Cl2, 0 –> 23 oC











Bi(OTf)3, PhCH3, 110 oC





control experiment, this reaction with aluminum chloride resulted in mixtures of 25, 26 and 27. As 
a result, we carried out several investigations to selectively synthesize 4-chromanone derivatives. 
Our research group had previously described the use of bismuth(III) trifluoromethanesulfonate as 
a catalyst for Friedel-Crafts cyclizations of tertiary alcohols to produce chromans as well as a 
variety of other heterocycles.69 Attempting to use the similar strategy with ester 24c revealed that 
the reaction of activated aryl esters with bismuth(III) trifluoromethanesulfonate afforded >70% of 
27c as the exclusive cyclized product, along with ca. 10% of the phenol from acid catalyzed 
cleavage of the starting ester.  Additional examples showed that this process appeared to be broadly 
applicable to many substrates (Scheme 2.8).   
Scheme 2.8 4-Chromanones from aryl esters of 3,3-dimethylacrylic acid 
We were primarily interested in developing an efficient, approach toward the preparation of 4-
chromanones. Rather than include another step by preparing the corresponding esters from 
relatively expensive 3,3-dimethylacryloyl chloride, we attempted to prepare the 4-chromanones 
directly from the corresponding phenol and 3,3-dimethylacrylic acid using bismuth(III) 
27b, 72% 27c, 72% 27d, 67% 






trifluoromethanesulfonate. This route selectively provided 4-chromanones in fair to excellent 
yields with none of the 2-chromanone products. Throughout the course of our investigation, the  
only substrates that failed to provide a clean conversion to the 4-chromanones were phenol and 2-
methylphenol. Additionally, we were also successful in expanding this process to cyclizations with 
crotonic acid.  To our displeasure, attempts to further expand this reaction for ring closures of trans-
cinnamic acid gave uncharacterizable mixtures with poor yields of the desired products. The results 
of our study of cyclizations using 3,3-dimethylacrylic acid and crotonic acid are shown in (Schemes 
2.9 and 2.10), respectively.   
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27b, (74%) 27c, (68%) 27d, (69%) 27e (44%)
27f, (65%) 27g, (45%) 27h, (25%) 27i, (88%)
27j, (76%) 27k, (87%) 27l, (77%) 27m, (84%)










Scheme 2.10 4-Chromanones from trans-crotonic acid 
All of the reactions were performed in toluene at reflux using a 1:1 ratio of phenol to carboxylic 
acid and 30 mol% of bismuth(III) triflate.  The mixtures were refluxed for 12-18 h while monitoring 
by TLC.  When maximum conversions were attained, the reactions were cooled, concentrated under 
28 30 
31b, (65%) 31c, (52%) 31d, (84%)  31e, (33%) 
31f, (71%)  31g,(55%) 31h, (45%)  31i, (45%) 





vacuum and the crude products, diluted with a small amount of chloroform, were applied to 
preparative thin layer chromatography (PTLC) plates.  Elution 3-4 times with 5% ether in hexane 
(8-10% ether in hexane was used for the methoxy-substituted products) yielded 2-3 bands.  In each 
case, the bright fluorescent blue band was the 4-chromanone, while others contained unreacted 
phenol or the aryl ester of the acid.  Our reaction proceeded in fair to high yields and tolerated a 
broad range of substrates. The 4-chromanone products were easily purified by preparative thin layer 
chromatography. Good yields were achieved with nearly all of the methyl-substituted derivatives, 
and in 3-substituted phenols where the two ortho carbons were unsubstituted, closure occurred 
toward the less hindered position.  Only 2-methylphenol failed to undergo a clean reaction, and this 
could derive from steric hindrance at the hydroxyl group as well as the fact that the single methyl 
substituent would exert only a minimal activating effect at the aromatic carbon that will attack the 
acylium electrophile during the Fries rearrangement.  Lower yields were also observed with 2,5-
disubstituted phenols (entries e and f), which were sterically hindered and also tended to sublime 
into the condenser. Lower yields were also observed with 3-chlorophenol (entry m), which could 
be attributed to the deactivating effect of the substituent.  On the contrary, the fluoro-substituted 
phenol (entry l) was unique in having an electron-withdrawing group while still providing a good 
yield of the desired chromanone product. This could be attributed to that fact fluorine-substituted 
aromatics show high reactivity in the para position relative to the fluorine.70-71 In 3-fluorophenol, 
the fluorine is para to the position that accepts the acylium ion during the Fries rearrangement, 
providing a much cleaner conversion was than expected. However, the yields of 4-chromanones 
were slightly lower for reactions involving crotonic acid, as might be predicted for a substrate with 
an impaired ability to stabilize the acylium ion intermediate. A plausible mechanism to the desired 
4-chromanone product is illustrated in (Scheme 2.11)
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Scheme 2.11. A plausible mechanism for the Bi(OTf)3 catalyzed synthesis of 4-chromanones 
Through careful monitoring by thin layer chromatography, the first intermediate in the process was 
identified the aryl ester 28c. The reason we chose toluene as a solvent, is to remove an equivalent 
of water produced in the reaction by azeotropic distillation into the condenser. The corresponding 
aryl ester would then undergo a Fries rearrangement to give 1-(2-hydroxy-4-methylphenyl)-3-
methylbut-2-en-1-one 26c. The failure of 26c to completely cyclize under the aluminum chloride 
conditions likely resulted from strong coordination of both the phenol and side chain ketone 
functions by the excess Lewis acid. This coordination would diminish the nucleophilicity of the 
ortho-hydroxyl group and slow the oxa-Michael addition to the enone double bond. Once ring 
closure occured in the bismuth(III) catalyzed reaction, proton transfer to generate 35, 




33 26c 34 
36 35 27c 
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2.2.6 Conclusion 
We were able to develop an efficient bismuth(III) triflate catalyzed tandem reaction to prepare 
substituted 4-chromonones from a wide range of substituted phenols and 3,3-dimethylacrylic acid 
or trans-crotonic acid. The procedure was convenient to perform, product purification was 
straightforward, and the target heterocycles were isolated in fair to excellent yields. A reasonable 
selection of substrates was surveyed to define the scope of the reaction. Limitations were 
predictably associated with deactivating groups on the aromatic nucleus and steric hindrance 
toward reattachment of the acyl group to the aromatic ring during the Fries rearrangement. 
Additionally, experiments confirmed that the sequence of events during the reaction involved (1) 
esterification of the acid by the phenol, (2) Fries rearrangement of the 2-butenyl acylium fragment 
to the less hindered ortho position and (3) oxa-Michael ring closure of the phenolic OH to the side 
chain enone of the Fries product.  
2.3 Chemistry  
General Methods: All reactions were run under dry nitrogen in oven-dried glassware. Reactions 
were monitored by thin layer chromatography on silica gel GF plates (Analtech, No. 21521). 
Preparative separations were performed by one of the following methods: (1) preparative thin layer 
chromatography (PTLC) on 20-cm × 20-cm silica gel GF plates (Analtech, No. 02015) or (2) 
column chromatography on silica gel (grade 62, 60–200 mesh) containing UV-active phosphor 
(Sorbent Technologies, No. UV-05) packed into quartz columns. Band elution for all 
chromatographic methods was monitored using a hand-held UV lamp. Melting points were 
uncorrected. FT-IR spectra were run as thin films on NaCl disks or as nujol mulls. Unless otherwise 
indicated, 1H and 13C NMR spectra were measured in CDCl3 using (CH3)4Si as the internal 
standard; coupling constants (J) are given in Hertz. Low-resolution mass spectra (electron 
impact/direct probe) were obtained at 70 eV. Elemental analyses (±0.4%) were performed by 





2.3.1 Naphthoates, dihydroquinolines carboxylates and naphthyridine carboxylates from 
MBH acetates.  
General Procedure for the synthesis of Morita-Bayliss-Hillman Adducts (9a-h):To a stirred 
solution of aldehyde 6a-e (1 equiv) and DABCO (1.5 equiv) in CH3CN (8 mL) under N2 was 
added the corresponding acrylate 7a-d (2 equiv) at room temperature. After 2 days, the solution 
was partitioned between H2O and EtOAc. The organic layer was washed with 1M HCl (2×) and 
saturated NaHCO3. The combined aqueous layers were back extracted with EtOAc (3×). All of 
the combined organic layers were washed with saturated NaCl and dried (Na2SO4). Removal of 
the solvent resulted in pure MBH adducts 9a-h, which were used without further purification.  
Ethyl 2-((2-fluoro-5-nitrophenyl)(hydroxy)methyl)acrylate (9a): Yield 0.45g (97%) as a 
colorless oil; IR:1748, 1725, 1632, 1532, 1351 cm-1; 1H NMR (CDCl3) δ 8.23 (dd, J = 6.1, 2.9 Hz, 
1H), 8.20 (ddd, J = 8.9, 4.2, 2.9 Hz, 1H), 7.20 (t, J = 8.9 Hz, 1H), 6.88 (s, 1H), 6.51 (s, 1H), 5.96 
(br d, J = 1.0 H3, 1H), 3.71 (s, 3H), 2.12 (s, 3H); 13C NMR (CDCl3): δ 165.9, 164.5 (d, J = 238.4 
Hz) 144.5, 139.8, 130.4 (d, J = 15.4 Hz ), 127.2 (d, J = 1.15 Hz ), 125.4(d, J = 10.3 Hz ), 124.7(d, 
J = 5.9 Hz ), 116.5, 116.2, 66.9, 61.5, 14.0.  
Methyl2-((2-fluoro-5-nitrophenyl)(hydroxy)methyl)acrylate(9b): Yield 0.35g (92%) as a 
yellow-orange  oil; IR: 3477, 1716, 1629, 1531, 1351 cm-1, 1H NMR (CDCl3): δ 8.47 (dd, J = 6.2, 
2.9 H, 1H), 8.21 (ddd, 9.0, 4.3, 2.9 Hz, 2H), 7.19 (t, J = 9.0 Hz, 1H), 6.41(s, 1H), 5.89 (br d, J = 2.4 
Hz), 5.81 (s, 1 H), 3.79 (s, 3H); OH not observed, poss 3.48; 13C NMR (CDCl3): δ 171.2, 166.4 (d, 
J = 240.2 Hz,), 155.9, 139.6, 130.4 (d, J = 15.4 Hz), 127.4, 125.4 (d, J = 10.3 Hz), 124.6 (d, J = 5.9 
Hz), 116.6, 116.3 (d, J = 2.7 Hz), 66.8, 60.4, 52.3, 21.1, 14.2. 
2,2,2-trifluoroethyl 2-((2-fluoro-5-nitrophenyl)(hydroxy)methyl)acrylate (9c) : Yield 0.25g 
(82%) as a light-gren oil; IR- 3341, 1746, 1545, 1368 cm-1;1H NMR (CDCl3): δ 8.44 (dd, J = 6.2, 
2.8 Hz, 1H), 8.23-8.21 (complex, 1H), 7.21 (t, J 8.9 Hz, 1H), 6.58 (s, 1H), 6.06 (s, 1H), 5.94 (s, 
1H), 4.53 (dq, J = 6.4 Hz, 2H), 13C NMR (CDCl3): δ 176.0, 164.3 (d, J= 242.2 Hz), 140.2, 138.8, 
61 
131.9, 129.4, 125.7 (d, J = 10.5 Hz), 124.6 (d, J = 5.8 Hz), 124.0 (d, J = 10.9 Hz), 121.2 (q, J = 
269.2 Hz) 116.7 (d, J = 4.7 Hz), 66.4 (d, J = 2.9 Hz), 61.0, 60.6.  
2-((2-fluoro-5-nitrophenyl)(hydroxy)methyl)acrylonitrile (9d): Yield 0.30g (80%) as a yellow 
oil; IR: 3451, 2232, 1636, 1530, 1348 cm-1; 1H NMR (CDCl3): δ 8.51 (dd, J = 6.1, 2.8 Hz, 1H), 
8.29 (ddd, J = 9.0, 4.4, 2.9  Hz, 1H), 7.27 (d, J = 9.0 Hz, 1H), 7.24 (s, 1H), 6.22 (t, J = 0.9 Hz, 1H), 
6.15 (d, J = 0.9 Hz, 1H), 5.72 (s, 1H); 13C NMR (CDCl3): δ 163.0 (d, J = 258.7 Hz), 144.8 (d, J = 
2.9 Hz), 131.60 , 128.4 (d, J = 15.3 Hz), 126.3 (d, J = 10.4 Hz), 124.2 (d, J =  8.4 Hz), 116.9, 116.7, 
115.9, 67.4.  
Ethyl 2-((2,5-difluorophenyl)(hydroxy)methyl)acrylate (9e):  Yield 0.42g (83%) as yellow oil; 
IR: 3451, 1713, 1631 cm-1; 1H NMR (CDCl3); δ 7.21 (ddd, J = 8.7, 6.0, 3.0 Hz, 1H), 7.03-6.92 
(complex, 2H), 6.35 (s, 1H), 5.80 (s, 1H), 5.73 (br d, J = 2.6 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 1.29 
(t, J = 7.1 Hz, 3H); OH not observed; 13C NMR (CDCl3): δ 166.3, 158.9 (dd, J = 242.7, 2.4 Hz) 
155.8 (dd, J = 242.7, 2.4 Hz) 140.4, 130.1 (dd, J = 16.9, 7.3 Hz), 126.6 (d, J = 0.9 Hz), 116.3 (dd, 
J = 24.6, 8.5 Hz)115.8 (dd, J = 24.6, 8.6 Hz), 114.8 (dd,  J = 25.2, 4.2 Hz), 67.0, 61.3, 14.0. 
Methyl  2-((2,5-difluorophenyl)(hydroxy)methyl)acrylate (9f) : Yield 0.54g (99%) as a yellow 
oil; IR: 3432, 1717, 1632 cm-1; 1H NMR (CDCl3): δ 7.21 (ddd, J = 8.7, 5.8, 3.0 Hz, 1H), 7.03-6.92 
(complex, 2H), 6.35 (s, 1H), 5.83 (br d, J = 2.7 Hz, 1H), 5.74 (q, J = 0.7 Hz, 1H), 3.78 (s, 3H), 3.33 
(d, J = 4.8 Hz, 1H); 13C NMR; δ 166.7, 158.9 (dd, J = 242.5, 1.3 Hz), 155.7 (dd, J = 242.7, 2.5 
Hz), 140.2, 130.0 (dd, J = 16.0, 7.3 Hz), 126.9, 116.4 (dd, J = 24.7, 8.5 Hz), 115.8 (dd, J = 24.2, 
8.6 Hz), 114.8 (dd, J = 25.2, 4.3 Hz), 67.0, 52.9. 
Ethyl 2-((2-fluoropyridin-3-yl)(hydroxy)methyl)acrylate (9g): Yield 0.50g (99%) as a colorless 
oil; IR: 3399, 1714, 1632 cm-1; 1H NMR (CDCl3): δ 8.16 (dt, J = 4.9, 1.6 Hz, 1H), 7.97 (ddd, J = 
9.5, 7.5, 1.9 Hz), 7.23 (ddd, J = 7.0, 4.9, 1.7 Hz, 1H), 6.35 (s, 1H), 5.78 (m, 1H), 5.76 (br d, J = 3.3 
Hz, 1H), 4.21 (qd, J = 7.1, 0.9 Hz, 2H), 3.56 (d, J = 5.5 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR 





139.1 (d, J = 2.5 Hz ) 127.6, 123.7 (d, J = 1.9 Hz), 123.4 (d, J = 2.0 Hz ), 121.7 (d, J =4.2 Hz), 
67.5, 61.3, 14.0.  
Methyl 2-((2-fluoropyridin-3-yl)(hydroxy)methyl)acrylate (9h): Yield 0.44g (96%) as a yellow 
oil; IR: 3336, 1714, 1627 cm-1; 1H NMR (CDCl3): δ 8.16 (dt, J = 4.9, 1.3 Hz, 1H), 7.97 (dddd, J = 
9.6, 7.5, 1.9, 0.6 Hz, 1H), 7.24 (ddd, J = 7.5, 4.9, 1.7 Hz, 1H), 6.38 (s, 1H), 5.79 (brs, 1H), 5.77 (d, 
J = 6.3 Hz, 1H), 3.77 (s, 3H); 13C NMR (CDCl3): δ 166.5, 161.5 (d, J = 239.2 Hz ), 146.7 (d, J = 
14.9 Hz) 139.4, 138.8 (d, J = 4.6 Hz) 127.2, 123.3 121.5 (d, J = 4.2 Hz), 67.4, 52.1. 
General Procedure for the synthesis of Morita-Bayliss-Hillman Acetates (10a-g):The 
corresponding MBH Adduct 9a-h was treated with 2 mL of acetic anhydride. The mixture was 
refluxed until complete consumption of the starting material. Excess acetic anhydride was removed 
under vacuum. The crude mixture was diluted with 20 mL of DCM and washed with 3 equal 
portions of saturated NaHCO3. Aqueous layers were back extracted with DCM (3×).  The combined 
organic layers were washed with H2O, saturated NaCl and dried (Na2SO4).  Removal of the solvent 
and purification by silica gel chromatography afforded the pure acetates 10a-g.  
Ethyl 2-(acetoxy(2-fluoro-5-nitrophenyl)methyl)acrylate (10a): Yield 0.40g (85%) as a 
colorless oil; IR: 1751, 1723, 1639, 1532, 1351 cm-1; 1H NMR (CDCl3): δ; 8.26 (dd, J = 6.0, 2.8 
Hz, 1H), 8.23 (ddd, J = 8.9, 4.3, 2.9 Hz, 1H), 7.22 (t, J = 8.9 Hz, 2H), 6.91 (s, 1H), 6.54 (s, 1H), 
4.18 (qd, J = 7.1, 1.3 Hz, 2H), 2.15 (s, 3H), 1.25 (q, J = 7.1 Hz, 3H); 13C NMR (CDCl3): δ 182.6, 
169.0, 164.22 (d, J = 232.5 Hz ), 144.2, 137.4, 127.4, 126.0 (d, J = 10.2 Hz ), 125.2 (d, J = 5.2 Hz), 
116.9, 116.7, 66.6, 61.4, 20.9, 13.9.  
Methyl 2-(acetoxy(2-fluoro-5-nitrophenyl)methyl)acrylate (10b): Yield 0.43g (82%) as a 
colorless oil;IR: 1748, 1725, 1632, 1532, 1351 cm-1; 1H NMR (CDCl3): δ; 8.23 dd, J = 6.1, 2.9 Hz, 
1H), 8.20 (ddd, J = 8.9, 4.2, 2.9 Hz, 1H), 7.20 (t, J = 8.9 Hz, 1H), 6.88 (s, 1H), 6.51 (s, 1H), 5.96 
(br d, J = 1.0 Hz, 1H), 3.71 (s, 3H), 2.12 (s, 3H); 13C NMR (CDCl3): δ 169.3, 165.4, 165.0 (d, J = 
63 
237.2 Hz ) 144.6, 137.5, 128.0, 127.7 (d, J = 15.6 Hz), 126.4 (d, J = 10.4 Hz ), 125.4 (d, J = 5.4 Hz 
), 117.4, 117.11, 66.9, 61.6, 52.5, 21.1. 
2-cyano-1-(2-fluoro-5-nitrophenyl)allyl acetate (10c): Yield 0.30g (84%) as a colorless oil;
IR: 2256, 1716, 1642, 1523 , 1356 cm-1; 1H NMR (CDCl3): δ 8.43 (dd, J = 6.1, 2.8 Hz, 1H), 8.31 
(ddd, J = 9.0, 4.4, 2.8 Hz, 1H), 7.29 (t, J = 9.0 Hz, 1H), 6.63 (s, 1H), 6.19 (s, 1H), 6.18 (s, 1H), 2.26 
(s, 3H); 13C NMR (CDCl3): δ 168.8, 164.4 (d, J = 262.1 Hz), 144.7, 133.7, 126.9 (d, J = 10.4 Hz), 
125.4 (d, J = 15.1 Hz), 124.1 (d, J = 4.9 Hz), 120.9, 117.3, 117.0, 115.2, 67.8, 20.8. 
Ethyl 2-(acetoxy(2,5-difluorophenyl)methyl)acrylate (10d): Yield 0.46g (88%) as a colorless 
oil; IR- 1752, 1723, 1638 cm-1; 1H NMR (CDCl3): δ 7.05-6.95 (complex, 3H), 6.88 (s, 1H), 6.47 
(s, 1H), 5.82 (s, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.12 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR 
(CDCl3): δ 169.1, 164.5 (d, J = 242.2 Hz), 158.5 156.2, 148.8, 138.2, 133.5, 126.9, 116.7 (ddd, 
24.7, 24.7, 8.5 Hz), 115.4 (dd, J = 25.0, 3.8 Hz), 62.0, 61.2, 20.9, 14.0.  
Methyl 2-(acetoxy(2,5-difluorophenyl)methyl)acrylate (10e):Yield 0.42g (94%) as a colorless 
oil; IR- 1751, 1728, 1637 cm-1; 1H NMR (CDCl3): δ7.06-6.95 (complex, 3H), 6.88 (s, 1H), 6.47 (s, 
1H), 5.84 (s, 1H), 3.74 (s, 3H), 2.13 (s, 3H); 13C NMR (CDCl3): δ 169.1, 165.0, 159.8 (dd, J = 
242.7, 2.4. Hz), 157.4 (dd, J = 245.6, 2.4 Hz), 155.0 (d, J = 2.6 Hz), 137.8, 127.3, 126.9 (d, J = 7.4 
Hz), 126.7 (d, J = 7.3 Hz), 117.0 (d, J = 8.5 Hz), 116.7 (dd, J = 8.6, 2.6 Hz), 116.5 (d, J = 8.6 Hz), 
115.5 (d, J = 3.7 Hz), 115.2 (d, J = 3.7 Hz), 67.1 (dd, J = 2.9,  0.84 Hz), 52.2, 20.9. 
Ethyl 2-(acetoxy(2-fluoropyridin-3-yl)methyl)acrylate (10f): Yield 0.30g (80%) as a colorless 
oil; IR: 1749, 1721, 1640 cm-1; 1H NMR (CDCl3): δ; 8.19 (d, J = 4.9 Hz, 1H), 7.81 (ddd, J = 9.3, 
7.6, 1.7 Hz, 1H), 7.19 (ddd, J = 7.6, 4.9, 1.4 Hz, 1H), 6.80 (s, 1H), 6.50 (s, 1H), 5.92 (s, 1H), 4.17 
(q, J = 7.1 Hz, 2H), 2.13 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3): δ 169.1, 164.4, 161.0 
(d, J = 242.1 Hz), 147.6 (d, J = 14.9 Hz), 140.1 (d, J = 4.4 Hz), 137.5, 127.2, 121.4 (d, J = 4.4 Hz), 
120.5 (d, J = 30.4 Hz), 67.8, 61.2, 20.9, 14.0. 
64 
Methyl 2-(acetoxy(2-fluoropyridin-3-yl)methyl)acrylate (10g): Yield 0.25g (75%) as a colorless 
oil;IR:1745, 1726, 1625 cm-1; 1H NMR (CDCl3): δ 8.19 (dt, J = 4.9, 1.3 Hz, 1H), 7.82 (ddd, J = 
9.4, 7.5, 1.9 Hz, 1H), 7.20 (ddd, J = 7.5, 4.9, 1.9 Hz, 1H), 6.79 (s, 1H), 6.50 (s, 1H), 5.95 (s, 1H), 
3.73 (s, 3H), 2.14 (s, 3H); 13C NMR (CDCl3): δ 169.1, 164.9 (d, J = 242.2 Hz) 162.2, 159.8, 147.7 
(d, J= 14.9 Hz), 137.2, 127.6, 121.4 (d, J = 4.4 Hz), 120.5, 120.3 67.9 ( d,  J= 4.42 Hz) 52.2, 20.9. 
General Procedure for the synthesis of cyclization with Morita-Bayliss-Hillman Acetates and 
active methylene compounds: A 50-mL, round-bottomed flask equipped with a condenser, stir 
bar and vacuum adapter, was charged with MBH acetate 10a (1 equiv) in 1 mL of DMF under N2. 
The corresponding active methylene compound (1.5 equiv) and K2CO3 (1.5 equiv) were added at 
room temperature with continued stirring. TLC indicated complete consumption of the starting 
material after 1 h. The solution was poured into 15 mL of de-ionized water, and extracted with 
EtOAc (3×). The combined organic layers were washed with NaCl and dried (Na2SO4). Removal 
of the solvent and trituration with 5% ether/pentane and filtration afforded the pure naphthalene 
carboxylates 11a-c.  
(11a) 
Ethyl 4-cyano-7-nitro-2-naphthoate (11a) from 10a and ethyl cyanoacetate: Yield: .70 mg 
(85%) as a tan solid m.p. 77-79 oC; IR: 1716, 1628, 1536, 1349, 1289, 1251 cm-1; 1H NMR 
(CDCl3): δ 8.91 (d, J = 2.3 Hz, 2H), 8.60 (d, J = 1.6 Hz 1H), 8.48 (dd, J = 9.2, 2.3 HZ, 1H), 8.36 
(d, J = 9.2 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3): δ 







Methyl 4-cyano-7-nitro-2-naphthoate (11b) from 10b and ethyl cyanoacetate: 
Yield: 55 mg (81%) as a  light brown solid m.p. 81-82 oC ; IR: 1720, 1531, 1440, 1349, 1293,  
1253 cm-1; 1H NMR (CDCl3): δ; 9.01 (d, J = 2.2 Hz, 2H), 8.70 (d, J = 1.5 Hz, 1H), 8.58 (dd, J = 
9.2, 2.2 Hz, 1H), 8.47 (d, J = 9.2 Hz, 1H), 4.06 (s, 3H); 13C NMR (CDCl3): δ 164.3, 146.7, 137.7, 
135.6, 135.3, 131.4, 128.6, 127.0, 126.8, 124.5, 118.2, 110.3, 53.0. 
(11c) 
Dimethyl 6-nitronaphthalene-1,3-dicarboxylate (11c) from 10b and methyl phenylsulfonyl 
acetate; Yield: 70 mg (96%) as na off-white solid m.p. 97-99 oC; IR:1720, 1625, 1532, 1379, 1302, 
1247 cm-1; 1H NMR (CDCl3): δ 9.22 (d, J = 9.5 Hz, 1H), 8.96 (d, J = 1.6 Hz, 1H), 8.94 (d, J =2.4 
Hz, 2H), 8.46 (dd, J = 9.5, 2.4 Hz, 1H), 4.07 (s, 3H), 4.05 (s, 3H); 13C NMR (CDCl3): δ 166.4, 
165.4, 146.6, 139.0, 137.1, 135.8, 133.0, 128.6, 128.2, 127.9, 125.9, 123.0, 52.9, 52.8. 
General Procedure for the of cyclization with Morita-Bayliss-Hillman Acetates with alkyl or 
aryl amines: A 50-mL, round-bottomed flask equipped with a condenser, stir bar and N2, was 
charged with the MBH acetate 10a-b (1 equiv) in 1 mL of DMF under N2. The corresponding amine 
(1.5 equiv) and K2CO3 (1.5 equiv) were added at room temperature with continued stirring. TLC 








15 mL of DI water, and extracted with EtOAc (3×). The organic layer was washed with 1M HCl 
(2×) and saturated NaHCO3 (2×). The combined organic layers were washed with NaCl and dried 
(Na2SO4). Removal of the solvent and trituration with 5% ether/pentane and filtration afforded the 
pure dihydroquinoline carboxylates 12a-f. 
   (12a) 
Ethyl 1-benzyl-6-nitro-1,2-dihydroquinoline-3-carboxylate from 10a and benzylamine 
Yield: 51 mg (80%) as a yellow solid m.p. 197-199 oC; IR:1705, 1574, 1322 cm-1;1H NMR 
(DMSO-d6): δ; 8.09 (d, J = 2.7 Hz, 1H), 7.91 (dd, J = 9.3, 2.7 Hz, 1H), 7.51 (s, 1H), 7.40-7.27 
(complex, 5H), 6.68 (d, J = 9.4 Hz, 1H), 4.66 (s, 2H), 4.52 (d, J = 1.1 Hz, 2H), 4.18 (q, J = 7.1 Hz, 
2H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (DMSO-d6): δ 164.0, 150.9, 136.5, 135.4, 133.3, 128.9,













from 10a and 2-aminobenzylamine: Yield: 64 mg (83%) as na organge solid : m.p. 140-141 oC; 
IR: (nujol): 3469, 3372, 1706, 1654, 1596, 1335 cm-1; 1H NMR (DMSO-d6): δ 8.08 (d, J = 2.7 H3,
1H), 7.92 (dd, J = 9.3, 2.7 Hz, 1H), 7.52 (s, 1H), 7.00 (t, J = 7.9 Hz, 1H), 6.83 (d, J = 7.5 Hz, 1H), 
6.72 (d, J = 7.9 H3, 1H), 6.53 (t, J = 7.5 Hz, 1H), 6.45 (d, J = 9.3 Hz, 1H), 5.01 (s, 2H), 4.49 (s, 
2H), 4.39 (s, 2H), 4.18 (q, J = 7.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (DMSO-d6): δ172.6,
150.8, 146.4, 136.2, 133.1, 127.6, 125.4, 122.4, 117.9, 116.9, 115.3, 113.6, 112.8, 109.5, 60.4, 57.6, 
49.5, 13.9. 
(12c) 
Ethyl 1-(4-morpholinophenyl)-6-nitro-1,2-dihydroquinoline-3-carboxylate from (10a) and 4-
morpholinoaniline: Yield 82 mg asan organge solid,  (72%)  m.p. 181-183 oC; IR: (nujol): 1707, 
1654, 1598, 1319, 1292 cm-1;1H NMR (DMSO-d6): δ; 8.14 (d, J = 2.7 Hz, 1H), 7.84 (dd, J = 9.3,
2.7 Hz, 1H), 7.56 (s, 1H), 7.28 (d, J = 8.9 Hz, 2H), 7.08 (d, J = 8.9 Hz, 2H), 6.17 (d, J = 9.3 Hz, 
1H), 4.69 (s, 2H), 4.19 (q, J = 7.1 Hz, 2H), 3.75 (t, J = 4.7 Hz, 4H), 3.17 (t, J = 4.7 Hz, 4H), 1.24 
(q, J = 7.1 Hz, 3H); 13C NMR (DMSO-d6): δ 164.4, 151.7, 150.7, 137.6, 134.7, 133.5, 128.3, 127.3, 














Ethyl 1-methyl-6-nitro-1,2-dihydroquinoline-3-carboxylate (12d) from 10a and methyl 
amine: Yield: 160mg (93%) as s yellow solid m.p. 117-118 oC; IR: (nujol) 1692, 1593, 1317 cm-
1;1H NMR (DMSO-d6): δ; 8.01 (d, J = 2.7 Hz, 1H), 7.95 (dd, J = 9.2, 2.7 Hz, 1H), 7.42 (s, 1H), 
6.60 (d, J = 9.2 Hz, 1H), 4.45 (brd, J = 1.1 Hz, 2H), 4.20 (q, J = 7.1 Hz, 2H), 2.92 (s, 3H), 1.26 (t, 
J = 7.1 Hz, 3H); 13C NMR (DMSO-d6): δ 164.5, 151.9, 136.7, 133.9, 128.9, 125.8, 123.1, 118.6, 





Methyl 1-(4-methoxybenzyl)-6-nitro-1,2-dihydroquinoline-3-carboxylate (12d) from 10b and 
4-hydroxy benzylamine: Yield: 130 mg (91%) as an orange solid m.p. 235-237 oC ; IR: (nujol); 
1704, 1656, 1596, 1326 cm-1;1H NMR (DMSO-d6): δ 9.42 (s, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.92 
(dd, J = 9.3, 2.4 Hz, 1H), 7.48 (s, 1H), 7.11 (d, J = 8.4 Hz, 2H), 6.76 (d, J = 8.4 Hz, 2H and s, 1H), 
4.51 (s, 2H), 4.46 (s, 2H), 3.72 (s, 3H); 13C NMR (DMSO-d6): δ 165.0, 157.3, 151.4, 136.7, 134.0, 














Methyl 6-nitro-1-phenyl-1,2-dihydroquinoline-3-carboxylate (12f) from 10b and aniline 
Yield: 120 mg (60%) as an organge m.p. 112-113 oC; IR: (nujol): 1711, 1652, 1567, 1374 cm-1;1H 
NMR (DMSO-d6): δ; 8.20 (d, J = 2.4 Hz, 1H), 7.88 (dd, J = 9.2, 2.4 Hz, 1H), 7.62 (s, 1H), 7.56 (t, 
J = 7.8 Hz, 2H), 7.45 (d, J = 7.7 Hz, 2H), 7.41 (t, J = 7.5 Hz, 1H), 6.30 (d, J = 9.3 Hz, 1H), 4.74 (s, 
2H), 3.74 (s, 3H); 13C NMR (DMSO-d6): δ 164.8, 151.0, 143.7, 138.2, 133.6, 130.9, 128.2, 128.1,
127.9, 126.3, 126.2, 123.2, 112.6, 52.5, 51.3.  
Synthesis of (13) 
The MBH adduct 10g (80 mg, .3 mmol) was suspended in 1 mL of methyl amine (12.1 M) under 
N2. The resulting fluorescent solution was treated with K2CO3 (620 mg, 0.45mmol) with continued 
stirring for 1 h. Then, the solution was cooled to 0 oC and treated with 5 mL of water resulting in 
the formation of a bright yellow solid.  The product was filtered and dried under vacum to afford 
13 (58 mg, 88%) as a fluorescent yellow solid  m.p. 65-66 oC; IR: 1701, 1646, 1556, 1395, 1222 
cm-1; 1H NMR (CDCl3): δ 7.95 (dd, J = 5.1, 1.8 Hz, 1H), 7.23 (t, J = 1.3 Hz, 1H) 7.10(dd, J = 7.2,
1.8 Hz, 1H) 6.42 (dd, J = 7.2, 2.1 Hz, 1H) 4.48 (d, J = 1.2 Hz, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.0 (s, 









112.5, 60.8, 51.1, 35.2, 14.3. 
2.3.2 Synthesis of 2-fluoro-5-nitronicotinaldehyde (23) 
Methyl 2-hydroxy-5-nitronicotinate (20) 
A 100-mL, round-bottomed flask, equipped with a stir bar, reflux condenser and a CaCl2 drying 
tube, was charged with 2-hydroxy-5-nitronicotinic acid71,72 19 (2.0 g, 10.9 mmol) in 25 mL of 
MeOH and 2-3 drops of conc. H2SO4. The mixture was heated to reflux for 8 hrs.  After the allotted 
time period, the mixture was cooled to room temperature resulting in the formation of a white 
precipitate. The solid was filtered and washed with 20 mL of cold MeOH and dried under vacuum 
to afford (2.0 g, 93%) of methyl 2-hydroxy-5-nitronicotinate as a white solid, m.p. 242-244°C; IR 
(nujol): 1726, 1655, 1576.4 1357, 1283 cm-1; 1H NMR (DMSO-d6): δ 13.2 (s, 1H), 8.9 (d, J = 3.3 
Hz, 1H), 8.6 ( d, J= 3.3 Hz, 1H), 3.8 (s, 3H); 13C NMR (DMSO-d6): δ 163.3, 158.3, 142.1, 137.7, 
128.8, 118.2, 52.1. 
Methyl 2-chloro-5-nitronicotinate (21) 
A 100-mL round-bottomed flask equipped with a stir bar, reflux condenser and a CaCl2 drying 
tube, was charged with methyl 2-hydroxy-5-nitronicotinate (20, 2.0 g, 10.1 mmol) in 10 mL of 
CHCl3. Thionyl chloride (7 mL) and DMF (0.5 mL) were added at room temperature. The solution 
was heated to 100°C for 6 h. The solution was cooled, and the volatiles were removed under 
vacuum. The resulting solution was treated with 25 mL of MeOH at 0 °C and stirred for 30 min. 
The solution was poured into 100 mL of H2O and extracted with EtOAc (150 mL). The organic 
layer was washed with H2O, saturated NaCl and dried (Na2SO4). Removal of the solvent afforded 
methyl 2-chloro-5-nitronicotinate (21) as a yellow crystalline solid (2.05 g, 93%), m.p 63-65°C IR: 
3080, 2954, 1744, 1600, 1567, 1438, 1351, 1271, 1063 cm-1; 1H NMR (CDCl3): δ 9.30 (d, J=2.8 
Hz, 1H), 8.92 (d, J= 2.7 Hz, 1H ), 4.12 (s, 3H); 13C NMR (CDCl3): δ 162.8,  155.5, 146.8, 142.7, 
135.3, 127.1, 53.6. 
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2-Chloro-5-nitronicotinaldehyde (22)
A three-neckED, 100-mL round-bottomed flask, equipped with a stir bar, reflux condenser and 
two-rubber septa was charged with methyl 2-chloro-5-nitronicotinate (21, 1.05 g, 4.84 mmol) in 
15mL of CH2Cl2 under N2. The solution was cooled to -78°C and DIBAL-H (1.5 M, 3.5 mL, 5.3 
mmol) was added dropwise over a 30-minute period. The mixture was stirred at -75°C for 1 h after 
which TLC analysis indicated the complete absence of starting material. The mixture was quenched 
at -70°C by the dropwise addition of 15 mL of saturated Rochelle’s salt (sodium potassium tartrate) 
solution. The ice bath was removed and the resulting orange solution was stirred for 10 min and 
poured into a separatory funnel and extracted with 30 mL of DCM (3×). The combined organic 
layers were washed with saturated NaCl and dried over (Na2SO4). Removal of the solvent and 
purification by silica gel chromatography using 5% EtOAc/Hex afforded 2-chloro-5-
nitronicotinaldehyde (22) as a yellow oil (795 mg, 88%). IR: 2876 1694, 1597, 1567, 1347, 1241, 
1072 cm-1; 1H NMR (CDCl3): δ 10.51 (s, 1H) 9.40 (d, J =2.8 Hz, 1H), 8.91 (d, J = 2.8 Hz, 1H ) ;
13C NMR (CDCl3): δ 186.8, 157.8, 148.7, 143.9, 132.9, 128.8. 
2-Fluoro-5-nitronicotinaldehyde (23)
To a solution of 2-chloro-5-nitronicotinaldehyde (22 , 532 mg, 2.9 mmol) in 15 mL of dry DMSO, 
was added KF (331 mg, 5.7mmol) under N2. The solution was heated at 70 °C for 2 h, then cooled 
to room temperature and poured into 50 mL of water. The aqueous layer was extracted (3×) with 
30 mL of EtOAc. The combined organic layers were washed with saturated NaCl and dried 
(Na2SO4). Removal of the solvent and purification by silica gel chromatography using 5% 
EtOAc/hex afforded 2-fluoro-5-nitronicotinaldehyde (23, 400 mg, 82%) as a white solid m.p. 50-
52°C IR: 2886, 1702, 1615, 1584, 1446, 1355 1238, 913.4 cm-1; 1H NMR (CDCl3): δ 10.4 (s, 1H) 
9.34 (dd, J = 2.9, 1.2 Hz, 1H), 9.15 (dd, J = 7.5, 2.9 Hz, 1H ) ; 13C NMR (CDCl3): δ 183.9, 166.6 
(d, J = 257.1 Hz), 149.1(d, J = 19.4 Hz), 143.3, 135.3 (d,  J = 5.1 Hz), 118.4 (d, J = 24.5 Hz); 19F 
NMR (CDCl3): δ -64.3 (d, J = 6.9 Hz) 
72 
2.3.3 A bismuth (III) trifluoromethanesulfonate catalyzed route to 4-chromonones  
Representative procedure for the preparation of aryl 3,3-dimethylacrylates.35  To an oil free 
suspension of NaH (0.60 g, 25.0 mmol) in 10 mL of anhydrous THF, a solution of the phenol (2.2g, 
23.1 mmol) in of THF (30 mL) was added over a 5-min period with stirring at 0 oC (ice bath). The 
solution was stirred for 10 min and then treated with a solution of 3-methyl-2-butenoyl chloride 
(2.78 g, 23.3 mmol) in THF (15 mL) over a 5-min period at 0 oC. The reaction was then allowed to 
warm to room temperature over a 3-h period. The white suspension was transferred to separatory 
funnel containing water (75 mL) and acetic acid (0.5 mL) and was gently shaken. The mixture was 
extracted with ether (2 × 50 mL), and the extract was washed with saturated NaCl (3 × 50 mL), 
dried (MgSO4), and concentrated to give a light-yellow oil. The product was purified on a 40-cm × 
2.5-cm silica gel column eluted with 10% ether in hexanes to give the pure ester.  
Phenyl 3-methyl-2-butenoate (24a): Yield:  3.61 g (20.6 mmol, 89%) as a colorless oil.  IR: 1738, 
1653 cm-1; 1H NMR (CDCl3): δ 7.38 (t, J = 7.9 Hz, 2H), 7.20 (t, J = 7.8 Hz, 1H), 7.10 (d, J = 8.0 
Hz, 2H), 5.91 (m, 1H), 2.22 (d, J = 1.8 Hz, 3H), 1.96 (d, J = 1.8 Hz, 3H); 13C NMR (100 CDCl3): 
δ 164.9, 159.9, 150.7, 129.3, 125.5, 121.8, 115.3, 27.6, 20.5; HRMS (ESI) m/z Calcd for [C11H12O2 
+ H]+: 177.0916; Found: 177.0910.
4-Methylphenyl 3-methyl-2-butenoate (24b):  Yield: 4.30 g (22.6 mmol, 98%) as a colorless oil;
IR: 1738, 1650 cm-1; 1H NMR (CDCl3): δ 7.16 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 5.90 
(s, 1H), 2.33 (s, 3H), 2.22 (s, 3H), 1.97 (s, 3H); 13C NMR (CDCl3): δ 165.1, 159.6, 148.4, 135.1, 
129.8, 121.5, 115.3, 27.6, 20.9, 20.5; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; 
Found: 191.1073. 
3-Methylphenyl 3-methyl-2-butenoate (24c): Yield:  4.25 g (22.4 mmol, 97%) as a colorless oil;
IR: 1739, 1647 cm-1; 1H NMR (CDCl3): δ 7.24 (t, J = 7.7 Hz, 1H), 7.02 (d, J = 7.7 Hz, 1H), 6.91 
(s, 1H), 6.89 (d, J = 7.7 Hz, 1H), 5.90 (s, 1H), 2.35 (s, 3H), 2.23 (s, 3H), 1.97 (s, 3H); 13C NMR 
(CDCl3): δ 165.1, 159.7, 150.6, 139.5, 129.1, 126.3, 122.4, 118.8, 115.3, 27.7, 21.3, 20.5; HRMS 
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(ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1062. 
3,5-Dimethylphenyl 3-methyl-2-butenoate (24d): Yield: 4.23 g (20.7 mmol, 89%) as a colorless 
oil; IR: 1734, 1650 cm-1; 1H NMR (CDCl3): δ 6.84 (s, 1H), 6.97 (s, 2H), 5.89 (s, 1H), 2.30 (s, 6H), 
2.22 (s, 3H), 1.97 (s, 3H); 13C NMR (CDCl3): δ 165.2, 159.5, 150.6, 139.1, 127.3, 119.4, 115.3, 
27.6, 21.2, 20.4; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+:  205.1229; Found: 205.1222.    
2-Isopropyl-5-methylphenyl 3-methyl-2-butenoate (24e):  Yield: 5.19 g (22.3 mmol, 96%) as a
colorless oil; IR: 1738, 1650 cm-1; 1H NMR (CDCl3): δ 7.19 (d, J = 7.9 Hz, 1H), 7.00 (d, J = 7.9 
Hz, 1H), 6.83 (s, 1H), 5.95 (apparent sextet, J = 1.3 Hz, 1H), 2.99 (d septet, J = 6.8, 1.3 Hz, 1H), 
2.32 (s, 3H), 2.23 (s, 3H), 1.99 (s, 3H), 1.19 (dd, J = 8.0, 1.9 Hz, 6H); 13C NMR (CDCl3): δ 165.2, 
159.5, 147.8, 137.2, 136.4, 126.8, 126.3, 123.0, 115.2, 27.6, 27.1, 23.1, 20.8, 20.5; HRMS (ESI) 
m/z Calcd for [C15H20O2 + H]+:  233.1542; Found: 233.1548. 
3-Fluorophenyl 3-methyl-2-butenoate (24f): Yield: 4.07 g (21.0 mmol, 90%) as a colorless oil;
IR: 1739, 1648, 1123 cm-1; 1H NMR (CDCl3): δ 7.34 (AB pattern, J = 7.8 Hz, 1H), 6.95-6.84 
(complex, 3H), 5.89 (s, 1H), 2.23 (s, 3H), 1.99 (s, 3H); 13C NMR (CDCl3): δ 164.4, 162.9 (d, J = 
247.0 Hz), 160.8, 151.6 (d, J = 10.8 Hz), 130.0 (d, J = 9.5 Hz), 117.6 (d, J  = 3.3 Hz), 114.8, 112.5 
(d, J = 21.0 Hz), 109.9 (d, J  = 24.1 Hz), 27.7, 20.6; HRMS (ESI) m/z Calcd for [C11H11FO2 + H]+:  
195.0821; found: 195.0825. 
3-Methoxyphenyl 3-methyl-2-butenoate (24g): Yield: 4.61 g (22.4 mmol, 96%) as a colorless
oil; IR: 2838, 1740, 1648 cm-1; 1H NMR (CDCl3): δ 7.26 (t, J = 8.2 Hz, 1H), 6.77 (ddd, J = 8.2, 
2.3, 0.7 Hz, 1H), 6.70 (ddd, J = 8.0, 2.3, 0.7 Hz, 1H), 6.66 (t, J = 2.3 Hz, 1H), 5.91 (s, 1H), 3.79 (s, 
3H), 2.23 (s, 3H), 1.98 (s, 3H); 13C NMR (CDCl3): δ 164.8, 160.4, 160.0, 151.7, 129.7, 115.2, 
114.1, 111.4, 107.7, 55.4, 27.6, 20.5; HRMS (ESI) m/z Calcd for [C12H14O3 + H]+: 207.1021; 
Found: 207.1017. 
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Reaction of 3-methylphenyl 3-methyl-2-butenoate with aluminum chloride:A 250-mL three-
necked, round-bottomed flask , equipped with a stir bar, an addition funnel and a condenser (with 
a drying tube) was charged with DCM (40 mL) and AlCl3 (1.19 g, 8.95 mmol).  The resulting 
suspension was stirred and cooled to 0 oC (ice bath), and a solution of 24c (1.00 g, 5.26 mmol) in 
DCM (10 mL) was added dropwise.  The reaction was gradually warmed to room temperature and 
stirring was continued for 65 h.  The resulting brown solution was added to a mixture of ice and 
saturated aq NaCl, the layers were separated, and the aqueous layer was extracted with DCM (40 
mL).  The combined organic extracts were washed with saturated NaCl (2 × 50 mL), dried 
(MgSO4), and concentrated to give a brown oil, which was purified on a 30 cm × 2.5 cm silica gel 
column eluted with increasing concentrations (2-10%) of ether in hexanes to give four bands:  band 
1 (highest Rf), 1-(2-hydroxy-4-methylphenyl)-3-methyl-2-buten-1-one (26c, 181 mg, 0.95 mmol, 
18%) as a yellow oil;  band 2, 3-methylphenyl 3-methyl-2-butenoate (24c, 51 mg, 0.26 mmol, 5%); 
band 3, 2,2,7-trimethyl-4-chromanone (27c, 648 mg, 3.41 mmol, 65%) as a white solid, m.p. 69-
70 oC; and band 4, 4,4,7-trimethyl-2-chromanone (25c, 21 mg, 0.011 mmol, 2%) as a yellow oil.  
The spectral data were as follows:   
Band 1 (26c):  IR: 3200-2700 (broad), 1640, 1583 cm-1; 1H NMR (CDCl3): δ 12.9 (s, 1H), 7.65 (d, 
J = 8.0 Hz, 1H), 6.78 (s, 1H), 6.74 (s, 1H), 6.68 (d, J = 8.0 Hz, 1H), 2.34 (s, 3H), 2.20 (s, 3H), 2.03 
(s, 3H); 13C NMR (CDCl3): δ 195.8, 163.4, 157.1, 147.3, 126.8, 120.1, 119.8, 118.5, 118.4, 28.2, 
21.9, 21.3; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; Found: 191.1065. 
Band 2 (24c) recovered starting material):  The spectral data matched those reported for 1c above. 
Band 3 (27c):  The spectral data matched those reported for 27c below. 
Band 4 (25c):  IR: 1772, 1625, 1581 cm-1; 1H NMR (CDCl3): δ 7.19 (d, J = 7.8 Hz, 1H), 6.96 (dd, 
J = 7.8, 1.7 Hz, 1H), 6.87 (d, J = 1.7 Hz, 1H), 2.60 (s, 2H), 2.33 (s, 3H), 1.33 (s, 6H); 13C NMR 
(CDCl3): δ 168.5, 150.5, 138.5, 128.7, 125.5, 124.2, 117.5, 43.8, 33.0, 27.8, 21.0; HRMS (ESI) m/z 






General procedure for the preparation of 4-chromanones from aryl 3,3-dimethylacrylates:A 
solution of the aryl 3,3-dimethylacrylate (24, 1.00 mmol) and bismuth(III) 
trifluoromethanesulfonate (131 mg, 20 mol%) in 8 mL of toluene was boiled for 12-24 h while 
monitored by TLC.  Each reaction was worked up by cooling, removing the solvent, diluting with 
1 mL of CHCl3, and applying the crude product mixture directly to a 20 cm × 20 cm PTLC plate.  
After the CHCl3 had been evaporated, the plate was eluted with 5% ether in hexanes (8-10% ether 
in hexanes for the methoxy-substituted products) to give three major bands.  The bright blue 
fluorescent band (the 4-chromanone) was accompanied by small amounts of the starting ester (a 
faster moving band) and the corresponding phenol (a slower moving band).  For 2-isopropyl-5-
methylphenol, the 4-chromanone (40%) was accompanied by larger quantities of aryl 3,3-
dimethylacrylate (12%) and phenol (30%).  The spectra for all of the 4-chromanones and some of 
the aryl esters isolated are listed below.   
Conversion of Fries product 26c to 4-chromanone 27c.  A toluene (8 mL) solution of 1-(2-hydroxy-
4-methylphenyl)-3-methyl-2-buten-1-one (26c, 60 mg, 0.31 mmol) and bismuth(III) 
trifluoromethansesulfonate (41 mg, 0.06 mmol, 20 mol%) was heated at reflux for 15 min.  The 
solvent was removed under vacuum and the remaining oil was filtered through a short plug of silica 
gel using 5% ether in hexanes.  Removal of the solvent under vacuum afforded 2,2,7-trimethyl-4-
chromanone (27c, 57 mg, 0.30 mmol, 95%).  The spectral data matched those reported for 27c 
below. 
General procedure for the preparation of 4-chromanones from the corresponding phenol and 
the carboxylic acids.  To a solution of the specific phenol (28, 1.0 mmol) and 29 or 30 (1.0 mmol) 
in 8 mL of toluene was added bismuth(III) trifluoromethansesulfonate (41 mg, 0.06 mmol, 20 
mol%).  The reaction was heated under reflux for 12-24 h and then cooled. Removal of the solvent 
under vacuum and purification by PTLC eluted with 5% ether in hexane (8-10% ether in hexanes 
for the methoxy-substituted products) showed several bands. The major band (bright fluorescent 
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blue) was isolated and extracted with ether to give the corresponding 4-chromanone 27or 31. The 
other bands consisted of varying amounts of the aryl ester of the carboxylic acid and unreacted 
substituted phenol. The following compounds were prepared by this method. 
2,2,6-Trimethyl-4-chromanone (27b):  Yield: 140 mg (0.74 mmol, 74%) as a colorless oil (lit74 
reports a m.p. of 67 oC); IR: 1692, 1619 cm-1; 1H NMR: (CDCl3): δ 7.65 (s, 1H), 7.28 (d, J = 8.4 
Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 2.69 (s, 2H), 2.34 (s, 3H), 1.45 (s, 6H); 13C NMR: (CDCl3): δ 
192.8, 158.0, 137.2, 130.0, 126.1, 119.8, 118.1, 79.0, 48.9, 26.6, 20.4; HRMS (ESI) m/z Calcd for 
[C12H14O2 + H]+: 191.1072; Found: 191.1077. 
2,2,7-Trimethyl-4-chromanone (27c):  Yield: 129 mg (0.68 mmol, 68%) as a white solid, m.p. 
69-70 oC (lit75 m.p. 70 oC); IR: 1686, 1617 cm-1; 1H NMR: (CDCl3): δ 7.75 (d, J = 8.0 Hz, 1H),
6.79 (d, J = 8.0 Hz, 1H), 6.73 (s, 1H), 2.69 (s, 2H), 2.30 (s, 3H), 1.44 (s, 6H); 13C NMR: (CDCl3): 
δ 192.2, 160.0, 149.6, 126.4, 122.0, 118.3, 118.0, 79.1, 48.8, 26.7, 21.9; HRMS (ESI) m/z Calcd 
for [C12H14O2 + H]+: 191.1072; Found: 191.1074. 
2,2,5,7-Tetramethyl-4-chromanone (27d): Yield: 140 mg (0.69 mmol, 69%) as a white solid, 
m.p. 61-63 oC; IR: 1682, 1614 cm-1; 1H NMR: (CDCl3): δ 6.60 (s, 1H), 6.57 (s, 1H), 2.67 (s, 2H),
2.59 (s, 3H), 2.28 (s, 3H), 1.43 (s, 6H); 13C NMR: (CDCl3): δ 194.1, 161.5, 146.3, 141.8, 125.6, 
116.9, 116.8, 78.4, 50.8, 27.0, 23.1, 22.1; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; 
Found: 205.1223. 
2,2,5-Trimethyl-8-isopropyl-4-chromanone (27e): Yield: 102 mg (0.44 mmol, 44%; 54% 
brsm—based on recovered phenol) as a white solid, m.p. 73-75 oC; IR: 1684, 1578 cm-1; 1H NMR: 
(CDCl3): δ 7.23 (d, J  = 7.7 Hz, 1H), 6.71 (d, J = 7.7 Hz, 1H), 3.25 (septet, J = 6.9 Hz, 1H), 2.70 
(s, 2H), 2.59 (s, 3H), 1.45 (s, 6H), 1.21 (d, J = 6.9 Hz, 6H); 13C NMR: (CDCl3): δ 194.6, 158.1, 
138.5, 135.3, 131.3, 123.4, 118.6, 77.8, 50.3, 26.9, 26.6, 22.7, 22.4; HRMS (ESI) m/z Calcd for 
[C15H20O2 + H]+: 233.1542; Found: 233.1541.  A faster moving band contained 2-isopropyl-5-
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methylphenyl 3-methyl-2-butenoate [ (X= 2-i-Pr-5-Me), 51 mg, 0.22 mmol, 22%; 27% brsm] as a 
colorless oil.  The spectral data matched those reported above. 
7-Fluoro-2,2-dimethyl-4-chromanone (27f): Yield: 126 mg (0.65 mmol, 65%) as a colorless oil;
IR: 1694, 1616 cm-1; 1H NMR: δ 7.78 (dd, J = 8.8, 6.8 Hz, 1H), 6.69 (td, J = 8.5, 2.4 Hz, 1H), 6.62 
(dd, J = 10.1, 2.4 Hz, 1H), 2.71 (s, 2H), 1.46 (s, 6H); 13C NMR: δ 191.1, 167.8 (d, J = 238.4 Hz), 
161.7 (d, J = 13.6 Hz), 129.0 (d, J = 11.4 Hz), 117.8 (d, J = 2.5 Hz), 109.7 (d, J = 22.7 Hz), 105.7 
(d, J = 24.3 Hz), 80.1, 48.6, 26.6; HRMS (ESI) m/z Calcd for [C11H11FO2 + H]+: 195.0821; found: 
195.0815. 
7-Methoxy-2,2-dimethyl-4-chromanone (27g): Yield: 93 mg (0.45 mmol, 45%) as a colorless
solid, m.p. 79-81 oC (lit154 m.p. 81-82 oC); IR: 2838, 1681, 1609 cm-1; 1H NMR: δ 7.79 (d, J = 8.8 
Hz, 1H), 6.55 (dd, J = 8.8, 2.4 Hz, 1H), 6.38 (d, J = 2.4 Hz, 1H), 3.83 (s, 3H), 2.67 (s, 2H), 1.46 (s, 
6H); 13C NMR: δ 191.1, 166.2, 162.0, 128.3, 114.1, 109.3, 101.1, 79.6, 55.4, 48.6, 26.7; HRMS 
(ESI) m/z Calcd for [C12H14O3 + H]+: 207.1021; found: 207.1012. 
2,2,5,8-Tetramethyl-4-chromanone (27h): Yield: 51 mg (0.25 mmol, 25%; 42% brsm) as a 
colorless oil; IR: 1688, 1586 cm-1; 1H NMR: δ 7.16 (d, J = 7.5 Hz, 1H), 6.64 (d, J = 7.5 Hz, 1H), 
2.69 (s, 2H), 2.58 (s, 3H), 2.17 (s, 3H), 1.44 (s, 6H); 13C NMR: δ 193.5, 159.0, 138.7, 135.5, 125.0, 
123.0, 118.4, 77.9, 50.3, 26.7, 22.6, 16.0; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; 
found: 205.1225.  A faster moving band contained 2,5-dimethylphenyl 3-methyl-2-butenoate [ (X 
= 2,5-diMe), 45 mg, 0.22 mmol, 22%; 37% brsm] as a colorless oil.  IR: 1734, 1649 cm-1; 1H NMR: 
δ 7.10 (d, J = 7.7 Hz, 1H), 6.94 (d, J = 7.7 Hz, 1H), 6.83 (s, 1H), 5.94 (apparent t, J = 0.7 Hz, 1H), 
2.31 (s, 3H), 2.23 (d, J = 0.7 Hz, 3H), 2.13 (s, 3H), 1.99 (d, J = 0.7 Hz, 3H); 13C NMR: δ 164.8, 
159.6, 149.1, 136.7, 130.7, 127.0, 126.5, 122.6, 115.1, 27.6, 20.9, 20.5, 15.8; HRMS (ESI) m/z 
Calcd for [C13H16O2 + H]+: 205.1229; found: 205.1221. 
2,2,6,7-Tetramethyl-4-chromanone (27i): Yield: 178 mg (0.87 mmol, 87%) as a white solid, m.p. 





2.20 (s, 3H), 1.43 (s, 6H); 13C NMR: δ 192.9, 158.7, 147.0, 129.7, 126.9, 119.3, 118.4, 79.4, 49.3, 
27.1, 20.9, 19.2; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; found: 205.1228. 
2,2,6,8-Tetramethyl-4-chromanone (27j): Yield: 155 mg (0.76 mmol, 76%) as a white solid, m.p. 
63-65 oC; IR: 1689, 1614 cm-1; 1H NMR: δ 7.51 (s, 1H), 7.16 (s, 1H), 2.69 (s, 2H), 2.26 (s, 3H), 
2.18 (s, 3H), 1.44 (s, 6H); 13C NMR: δ 193.3, 156.3, 138.1, 129.2, 127.3, 123.6, 119.4, 78.6, 49.8, 
26.7, 20.3, 15.7; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; found: 205.1221. 
2,2,7,8-Tetramethyl-4-chromanone (27k): Yield: 177 mg (0.87 mmol, 87%) as a white solid, 
m.p. 52-54 oC; IR: 1688, 1604 cm-1; 1H NMR: δ 7.62 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 
2.67 (s, 2H), 2.29 (s, 3H), 2.14 (s, 3H), 1.45 (s, 6H); 13C NMR: δ 193.5, 158.3, 146.0, 125.9, 123.7, 
122.7, 118.5, 49.1, 27.3, 21.2, 11.9; HRMS (ESI) m/z Calcd for [C13H16O2 + H]+: 205.1229; found: 
205.1233. 
3,3-Dimethyl-2,3-dihydro-1H-benzo[f]chromen-1-one (27l): Yield: 174 mg (0.77 mmol, 77%) 
as a light yellow solid, m.p. 78-80 oC; IR: 1672, 1618 cm-1; 1H NMR: δ 9.44 (d, J = 8.7 Hz, 1H), 
7.89 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 
7.05 (d, J = 9.0 Hz, 1H), 2.82 (s, 2H), 1.51 (s, 6H); 13C NMR: δ 193.6, 162.0, 137.3, 131.3, 129.5, 
128.8, 128.3, 125.5, 124.5, 119.4, 111.4, 79.4, 50.1, 26.3; HRMS (ESI) m/z Calcd for [C15H14O2 + 
H]+: 227.1072; found: 227.1068. 
2,2-Dimethyl-2,3,6,7,8,9-hexahydro-4H-benzo[g]chromen-4-one (27m): Yield: 193 mg (0.84 
mmol, 84%) as a white solid, m.p. 75-76 oC; IR: 1687, 1618 cm-1; 1H NMR: δ 7.56 (s, 1H), 6.63 (s, 
1H), 2.76 (m, 4H), 2.67 (s, 2H), 1.77 (m, 4H), 1.43 (s, 6H); 13C NMR: δ 192.6, 157.6, 147.1, 129.9, 
126.3, 118.2, 117.7, 78.8, 49.0, 30.7, 28.4, 26.7, 23.2, 22.7; HRMS (ESI) m/z Calcd for [C15H18O2 
+ H]+: 231.1385; found: 231.1377. 
7-Chloro-2,2-dimethyl-4-chromanone (27n): Yield: 84 mg (0.40 mmol, 40%; 48% brsm) as a 
white solid, m.p. 69-70 oC; IR: 1694, 1599 cm-1; 1H NMR: δ 7.79 (d, J = 9.0 Hz, 1H), 6.95 (m, 2H), 
2.71 (s, 2H), 1.46 (s, 6H); 13C NMR: δ 191.5, 160.4, 141.9, 127.8, 121.5, 118.7, 118.5, 80.0, 48.7, 
26.6; HRMS (ESI) m/z Calcd for [C11H11ClO2 + H]+: 211.0526; found: 211.0529.  A faster moving 
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band contained 3-chlorophenyl 3-methyl-2-butenoate [1m (X = 3-Cl), 55 mg, 0.26 mmol, 26%; 
31% brsm] as a colorless oil.  IR:  1742, 1649 cm-1; 1H NMR: δ 7.30 (t, J = 8.1 Hz, 1H), 7.20 (dm, 
J = 9.0 Hz, 1H), 7.15 (t, J = 2.4 Hz, 1H), 7.01 (dm, J = 8.1 Hz, 1H), 5.89 (s, 1H), 2.24 (s, 3H), 2.00 
(s, 3H); 13C NMR: δ 164.4, 160.9, 151.2, 134.6, 130.1, 125.8, 122.5, 120.2, 114.8, 27.7, 20.6; 
HRMS (ESI) m/z Calcd for [C11H11ClO2 + H]+: 211.0526; found: 211.0520. 
6-Methoxy-2,2-dimethyl-4-chromanone (27o):  Yield: 165 mg (0.80 mmol, 80%) as a light
yellow solid, m.p. 69-71 oC; IR: 2834, 1686, 1619 cm-1; 1H NMR: δ 7.29 (s, 1H), 7.08 (d, J = 9.0 
Hz, 1H), 6.85 (d, J = 9.0 Hz, 1H), 3.79 (s, 3H), 2.70 (s, 2H), 1.44 (s, 6H); 13C NMR: δ 193.1, 155.1, 
154.0, 125.8, 120.4, 120.1, 107.4, 79.5, 56.2, 49.3, 27.0; HRMS (ESI) m/z Calcd for [C12H14O3 + 
H]+: 207.1021; found: 207.1015. 
(±)-2,6-Dimethyl-4-chromanone (31b): Yield: 114 mg (0.65 mmol, 65%) as a yellow oil; IR: 
1691, 1618 cm-1; 1H NMR: δ 7.67 (d, J = 2.4 Hz, 1H), 7.28 (dd, J = 8.4, 2.4 Hz, 1H), 6.87 (d, J = 
8.4 Hz, 1H), 4.55 (m, 1H), 2.67 (AB pattern, J = 16.9 Hz, 1H), 2.65 (s, 1H), 2.30 (s, 3H), 1.51 (d, 
J = 6.3 Hz, 3H); 13C NMR: δ 192.8, 159.8, 137.1, 130.6, 126.5, 120.4, 117.7, 74.2, 44.7, 21.0, 20.4; 
HRMS (ESI) m/z Calcd for [C11H12O2 + H]+: 177.0916; found: 177.0913.  
(±)-2,7-Dimethyl-4-chromanone (31c): Yield: 91 mg (0.52 mmol, 52%) as a light yellow oil; IR: 
1689, 1615 cm-1; 1H NMR: δ 7.77 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 6.77 (s, 1H), 4.56 
(m, 1H), 2.66 (AB pattern, J = 16.5 Hz, 1H), 2.64 (s, 1H), 2.35 (s, 3H), 1.50 (d, J = 6.3 Hz, 3H); 
13C NMR: δ 192.3, 161.7, 147.5, 126.8, 122.6, 118.6, 117.9, 74.3, 44.6, 21.9, 21.0; HRMS (ESI) 
m/z Calcd for [C11H12O2 + H]+: 177.0916; found: 177.0921.  
(±)-2,5,7-Trimethyl-4-chromanone (31d): Yield: 159 mg (0.84 mmol, 84%) as a white solid, m.p. 
53-54 oC; IR: 1681, 1613 cm-1; 1H NMR: δ 6.64 (s, 1H), 6.60 (s, 1H), 4.51 (m, 1H), 2.65-2.58
(obscured pattern, 2H), 2.60 (s, 3H), 2.29 (s, 3H), 1.47 (d, J = 6.3 Hz, 3H); 13C NMR: δ 193.6, 
162.8, 145.8, 141.8, 125.8, 117.1, 115.9, 73.5, 46.1, 22.7, 21.7, 20.9; HRMS (ESI) m/z Calcd for 
[C12H14O2 + H]+: 191.1072; found: 191.1070.  
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(±)-2,5-Dimethyl-8-isopropyl-4-chromanone (31e): Yield: 72 mg (0.33 mmol, 33%; 40% brsm) 
as a white solid, m.p. 64-65 oC; IR: 1685, 1579 cm-1; 1H NMR: δ 7.24 (d, J = 7.8 Hz, 1H), 6.75 (d, 
J = 7.7 Hz, 1H), 4.52 (m 1H), 3.28 (septet, J = 6.9 Hz, 1H), 2.68 (AB pattern, J = 16.8 Hz, 1H), 
2.65 (s, 1H), 2.60 (s, 3H), 1.51 (d, J = 6.2 Hz, 3H), 1.21 (d, J = 6.9 Hz, 6H); 13C NMR: δ 195.1, 
160.5, 139.5, 135.5, 131.7, 124.5, 119.8, 73.8, 46.6, 27.2, 23.2, 23.0, 22.9, 21.4; HRMS (ESI) m/z 
Calcd for [C14H18O2 + H]+: 219.1385; found: 219.1388. A faster moving band contained 2-
isopropyl-5-methylphenyl (E)-2-butenoate [ (X = 2-i-Pr-5-Me), 72 mg, 0.33 mmol, 33%; 40% 
brsm] as a light yellow oil; IR: 1739, 1659 cm-1; 1H NMR: δ 7.24-7.14 (complex, 2H), 7.02 (d, J = 
7.9 Hz, 1H), 6.83 (s, 1H), 6.07 (dd, J = 15.5, 1.5 Hz, 1H), 2.98 (septet, J = 6.9 Hz, 1H), 2.32 (s, 
3H), 1.97 (dd, J = 7.0, 1.8 Hz, 3H), 1.19 (d, J = 6.9 Hz, 6H); 13C NMR: δ 165.1, 147.9, 146.7, 
137.1, 136.5, 127.0, 126.4, 122.8, 122.1, 27.1, 23.0, 20.8, 18.2; HRMS (ESI) m/z Calcd for 
[C14H18O2 + H]+: 219.1385; found: 219.1378.  
(±)-7-Fluoro-2-methyl-4-chromanone (31f): Yield: 128 mg (0.71 mmol, 71%) as a light yellow 
oil; IR: 1695, 1612 cm-1; 1H NMR: δ 7.89 (dd, J = 8.8, 6.6 Hz, 1H), 6.72 (td, J = 8.4, 2.4 Hz, 1H), 
6.65 (dd, J = 10.1, 2.4 Hz, 1H), 4.61 (m, 1H), 2.68 (s, 1H), 2.66 (AB, J = 16.4 Hz, 1H), 1.51 (d, J 
= 6.3 Hz, 3H); 13C NMR: δ 191.1, 167.4 (d, J = 256.0 Hz), 163.3 (d, J = 13.7 Hz), 129.4 (d, J = 
11.4 Hz), 117.7 (d, J = 2.6 Hz), 109.6 (d, J = 22.7 Hz), 104.6 (d, J = 24.3 Hz), 74.9, 44.1, 20.8; 
HRMS (ESI) m/z Calcd for [C10H9FO2 + H]+: 181.0664; found: 181.0661.  
(±)-7-Methoxy-2-methyl-4-chromanone (31g): Yield: 105 mg (0.55 mmol, 55%) as a yellow 
solid, m.p. 67-69 oC; IR: 2839, 1682, 1607 cm-1; 1H NMR: δ 7.52 (d, J = 8.8 Hz, 1H), 6.57 (dd, J 
= 8.8, 2.4 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 4.59 (m, 1H), 3.83 (s, 3H), 2.64 (AB, J = 16.8 Hz, 
1H), 2.62 (s, 1H), 1.51 (d, J = 6.3 Hz, 3H); 13C NMR: δ 191.1, 166.0, 163.6, 128.7, 114.8, 109.8, 
100.7, 74.7, 55.6, 44.3, 21.0; HRMS (ESI) m/z Calcd for [C11H12O3 + H]+: 193.0865; found: 
193.0859. 
(±)-2,5,8-Trimethyl-4-chromanone (31h): Yield: 80 mg (0.42 mmol, 42%; 47% brsm) as a light 
yellow oil; IR: 1685, 1583 cm-1; 1H NMR: δ 7.17 (d, J = 7.5 Hz, 1H), 6.68 (d, J = 7.5 Hz, 1H), 4.53 
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(m, 1H), 2.67 (AB pattern, J = 16.6 Hz, 1H), 2.64 (s, 1H), 2.59 (s, 3H), 2.19 (s, 3H), 1.50 (d, J = 
6.3 Hz, 3H); 13C NMR:   194.9, 161.3, 139.6, 135.9, 125.1, 124.0, 118.8, 73.8, 46.5, 23.2, 21.4, 
16.3; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1066.  A faster moving 
band contained 2,5-dimethylphenyl (E)-2-butenoate [ (X = 2,5-diMe), 67 mg, 0.35 mmol, 35%; 
39% brsm] as a colorless oil; IR: 1739, 1656 cm-1; 1H NMR:   7.16 (dq, J = 15.5, 6.9 Hz, 1H), 
7.10 (d, J = 7.7 Hz, 1H), 6.94 (d, J = 7.7 Hz, 1H), 6.84 (s, 1H), 6.07 (dq, J = 15.5, 1.7 Hz, 1H), 
2.31 (s, 3H), 2.12 (s, 3H), 1.96 (dd, J = 6.9, 1.7 Hz, 3H); 13C NMR: δ 164.7, 149.2, 146.7, 136.8, 
130.8, 127.0, 126.7, 122.5, 122.0, 20.9, 18.2, 15.8; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 
191.1072; found: 191.1062.   
(±)-2,6,7-Trimethyl-4-chromanone (31i): Yield: 136 mg (0.72 mmol, 72%) as a tan solid, m.p. 
73-75 oC; IR: 1681, 1621 cm-1; 1H NMR: δ 7.61 (s, 1H), 6.76 (s, 1H), 4.55 (m, 1H), 2.64 (AB
pattern, J = 16.9 Hz, 1H), 2.62 (s, 1H), 2.26 (s, 3H), 2.21 (s, 3H), 1.49 (d, J = 6.3 Hz, 3H); 13C 
NMR: δ 192.5, 160.0 146.5, 129.8, 126.9, 118.6, 118.3, 74.2, 44.6, 21.0, 20.5, 18.8; HRMS (ESI) 
m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1075.  
(±)-2,6,8-Trimethyl-4-chromanone (31j): Yield: 68 mg (0.36 mmol, 36%; 44% brsm) as a light 
yellow solid, m.p. 48-51 oC; IR: 1692,1616 cm-1; 1H NMR: δ 7.53 (s, 1H), 7.16 (s, 1H), 4.54 (m, 
1H), 2.65 (apparent s, 1H), 2.63 (s, 1H), 2.26 (s, 3H), 2.21 (s, 3H), 1.52 (d, J = 6.3 Hz, 3H); 13C 
NMR: δ 193.2, 158.1, 138.0, 129.8, 126.8, 124.0, 120.1, 74.0, 44.6, 21.0, 20.4, 15.6; HRMS (ESI) 
m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1064.  A faster moving band contained 2,4-
dimethylphenyl (E)-2-butenoate [(X = 2,4-diMe), 57 mg, 0.30 mmol, 30%; 37% brsm] as a light 
yellow oil;  IR: 1740, 1657 cm-1; 1H NMR: δ 7.19 (dq, J = 16.9, 6.9 Hz, 1H), 7.03 (s, 1H), 7.00 (d, 
J = 8.1 Hz, 1H), 6.90 (d, J = 8.1 Hz, 1H), 6.07 (dd, J = 16.9, 1.8 Hz, 1H), 2.30 (s, 3H), 2.13 (s, 3H), 
1.96 (dd, J = 6.9, 1.8 Hz, 3H); 13C NMR: δ 164.8, 147.1, 146.6, 135.4, 131.7, 129.8, 127.4, 122.0, 
121.6, 20.8, 18.2, 16.1; HRMS (ESI) m/z Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1066. 
(±)-2,7,8-Trimethyl-4-chromanone (31k): Yield: 152 mg (0.80 mmol, 80%) as a yellow oil; IR: 
1688, 1604 cm-1; 1H NMR: δ 7.66 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 4.55 (m, 1H), 2.65 
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(s, 1H), 2.63 (AB, J = 16.5 Hz, 1H), 2.30 (s, 3H), 2.16 (s, 3H), 1.53 (d, J = 6.3 Hz, 3H); 13C NMR: 
δ 192.8, 159.5, 145.3, 124.9, 123.5, 122.6, 118.5, 73.9, 44.2, 20.9, 20.5, 11.2; HRMS (ESI) m/z 
Calcd for [C12H14O2 + H]+: 191.1072; found: 191.1067.  
(±)-3-Methyl-2,3-dihydro-1H-benzo[f]chromen-1-one (31l): Yield: 159 mg (0.75 mmol, 75%) 
as a white solid, m.p. 66-68 oC; IR: 1667, 1618 cm-1; 1H NMR: δ 9.45 (d, J = 8.1 Hz, 1H), 7.91 (d, 
J = 9.0 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.10 
(d, J = 9.0 Hz, 1H), 4.71 (m, 1H), 2.87-2.69 (complex, 2H), 1.57 (d, J = 6.0 Hz, 3H); 13C NMR: δ 
193.4, 163.6, 137.2, 131.1, 129.4, 128.9, 128.1, 125.6, 124.6, 118.7, 112.2, 74.2, 45.6, 20.5; HRMS 
(ESI) m/z Calcd for [C14H12O2 + H]+:  213.0916; found: 213.0909.  
(±)-2-Methyl-2,3,6,7,8,9-hexahydro-4H-benzo[g]chromen-4-one (31m): Yield: 112 mg (0.52 
mmol, 52%) as a light yellow solid, m.p. 60-61 oC; IR: 1686, 1618 cm-1; 1H NMR: δ 7.58 (s, 1H), 
6.67 (s, 1H), 4.51 (m, 1H), 2.72 (dm, J = 15.8 Hz, 4H), 2.64 (AB, J = 15.8 Hz, 1H), 2.62 (s, 1H), 
1.77 (m, 4H), 1.48 (d, J = 6.3 Hz, 3H); 13C NMR: δ 192.6, 159.3, 146.9, 130.5, 126.7, 118.8, 117.2, 
74.1, 44.7, 30.1, 28.5, 23.1, 22.7, 21.0; HRMS (ESI) m/z Calcd for [C14H16O2 + H]+: 217.1229; 
found: 217.1232.  
(±)-7-Chloro-2-methyl-4-chromanone (31n): Yield: 52 mg (0.26 mmol, 36%; 46% brsm) as a 
white solid, m.p. 53-55 oC; IR: 1690, 1598 cm-1; 1H NMR: δ 7.81 (d, J = 8.2 Hz, 1H), 7.00 (s, 1 H), 
6.99 (dd, J = 8.2, 2.0 Hz, 1H), 4.61 (m, 1H), 2.69 (s, 1H), 2.67 (AB pattern, J = 16.8 Hz, 1H), 1.52 
(d, J = 6.3 Hz, 3H),; 13C NMR: δ 191.2, 161.8, 141.6, 128.0, 121.9, 119.2, 117.9, 74.7, 44.2, 20.7; 
HRMS (ESI) m/z Calcd for [C10H9ClO2 + H]+: 197.0369; found: 197.0376.  A faster moving band 
contained 3-chlorophenyl (E)-2-butenoate [(X = 3-Cl), 43 mg, 0.22 mmol, 22%; 28% brsm] as a 
light yellow oil; IR: 1736, 1655 cm-1; 1H NMR: δ 7.30 (t, J = 8.1 Hz, 1H), 7.24-7.14 (complex, 
3H), 7.03 (d, J = 8.2 Hz, 1H), 6.03 (d, J = 15.5 Hz, 1H), 1.98 (dd, J = 6.9, 1.7 Hz, 3H); 13C NMR: 
δ 164.2, 151.1, 147.4, 134.4, 129.9, 125.8, 122.2, 121.5, 119.9, 18.1; HRMS (ESI) m/z Calcd for 
[C10H9ClO2 + H]+: 197.0369; found: 197.0362.    
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(±)-6-Methoxy-2-methyl-4-chromanone (31o): Yield: 99 mg (0.52 mmol, 52%) as an orange 
solid, mp 58-61 oC; IR: 2834, 1689, 1621 cm-1; 1H NMR: δ 7.31 (d, J = 3.2 Hz, 1H), 7.09 (dd, J = 
9.0, 3.2 Hz, 1H), 6.91 (d, J = 9.0 Hz, 1H), 4.55 (m, 1H), 3.80 (s, 3H), 2.67 (apparent br s, 1H), 2.65 
(s, 1H), 1.51 (d, J = 6.3 Hz, 3H); 13C NMR: δ 193.1, 156.9, 154.4, 125.7, 121.7, 119.6, 107.7, 74.8, 
56.3, 45.0, 21.4; HRMS (ESI) m/z Calcd for [C11H12O3 + H]+: 193.0865; found: 193.0866.  
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